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This thesis examined several aspects of biliary physiology, the incidence of the
post-cholecystectomy syndrome and changes in sphincter of Oddi (SO) motility
following cholecystectomy.
Gallbladder emptying starts before the stomach begins to empty and before nutrients
reach the small bowel to stimulate cholecystokinin (CCK) release. The mechanism
of the early phase of gallbladder emptying is unclear. Gallbladder emptying was
examined in a group of volunteers after ingestion of a fatty meal, a sham meal and
gaseous gastric distension. The early phase of gallbladder emptying was found to be
associated with CCK release. In most cases, gaseous gastric distension and sham
feeding did not cause significant gallbladder emptying or CCK release but in a
minority of individuals early gallbladder emptying followed sham feeding and this
was associated with increased plasma CCK concentrations. Early release of CCK
could be mediated by a combination of vagal-cholinergic stimulation and
neuro-hormonal reflex in response to bombesin release by intragastric nutrients.
The effect of nitric oxide (NO) upon gallbladder motility was examined in a group of
volunteers after fatty meal during infusion with NO donors (glyceryltrinitrate and
sodium nitroprusside), normal saline and hydralazine as a hypotensive control agent.
Postprandial gallbladder emptying was significantly reduced during infusion with the
NO donors. This inhibitory effect was independent of hypotension and CCK release.
This inhibitory effect of NO donors was also observed on isometric contraction of
isolated gallbladder muscle strips.
The effect ofNO on the SO was examined by topical infusion of glyceryltrinitrate to
the ampulla during SO manometry. Basal tone and phasic activity were both
suppressed. This finding may have therapeutic application for stone extraction and
duct cannulation during endoscopic retrograde cholangiopancreatography.
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Symptoms were assessed in 100 patients before and six months after laparoscopic
cholecystectomy (LC) with standard questionnaire. 13% of patients had persistent
biliary symptoms. Pre-operative abdominal bloating and consumption of
antidepressant were found to be significantly more prevalent in these subjects
compared to padents who had successful operations.
SO dysfunction is a cause of post-cholecystectomy pain. We hypothesised that LC
could destroy cholecysto-sphincteric nerves leading to SO dysfunction. SO
manometry was performed in a group of volunteers before and six months after LC.
Following LC, the SO was not inhibited by CCK. This could lead to relative
post-prandial biliary obstruction and result in post-cholecystectomy pain in
susceptible individuals and to dilatation of the common bile duct.
Several issues and concepts arose from the work of this thesis. The mechanism
underlying the early release of CCK needs further investigation. The clinical
relevance of the effects ofNO upon biliary tract motility remains to be explored. It is





CBD Common bile duct
EFS Electrical field stimulation
ERCP Endoscopic retrograde cholangiopancreatography

















NOS Nitric oxide synthase
PC Post-cholecystectomy
QHBS Quantitative hepatobiliary scintigraphy
SEM Standard error mean
SD Standard deviation
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PART ONE
INTRODUCTION AND LITERATURE REVIEW
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CHAPTER ONE
BILIARY TREE - ANATOMY AND PHYSIOLOGY
1.1 Introduction
Diseases of the gallbladder are common and affect 10 to 20% of the world's
population. Biliary motility involves a series of complex interrelationship between
gallbladder, cystic duct, common bile duct, sphincter of Oddi (SO) and upper small
intestine. Neural and hormonal factors modulate these relationships. Alterations in
biliary motility are increasingly implicated in the aetiology of gallstones and
post-cholecystectomy pain. The application of modem techniques, such as
ultrasonography and SO manometry, to the study of the biliary tract has allowed a
better understanding of biliary physiology. This thesis examined aspects of biliary
physiology and alterations which occur after cholecystectomy.
1.2 Gallbladder
1.2.1 Anatomy
The gallbladder is a piriform, muscular sac and lies in a depression on the inferior
surface of the liver at the junction of the right and left lobes known as the "gallbladder
bed". It is divided into four areas: the fundus, the body, the infundibulum and the neck.
The fundus is the expanded end lying nearest the abdominal wall, usually at the
junction of the ninth costal cartilage and the right rectus abdominis muscle. The body
constitutes the major portion of the gallbladder. It is in direct contact with the first
portion of the duodenum and the hepatic flexure of the colon. Inflammation from
gallstones can cause a fistula between the gallbladder and the duodenum or between the
gallbladder and the colon. It is continuous with the infundibulum, a transitional area
that leads to the narrow neck, which, in turn opens into the cystic duct. Hartman's
pouch is a sacculation on the inferior surface of the infundibulum. Gallstones can
impact and become trapped in Hartman's pouch, causing obstruction of the cystic duct
and acute cholecystitis. Sometimes the inflammatory process can produce obstruction
of the common bile duct; the "Mirizzi syndrome".
Histologically, the gallbladder has four layers: mucosa, muscularis, a perimuscularis
connective tissue and the serosa. The outermost serosal layer is deficient on the surface
of the organ that is in direct contact with the liver. The fibromuscular layer is
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composed of fibrous tissues mixed with smooth muscle loosely arranged in
longitudinal, circular and oblique bundles. The mucosa consists of a glandular
epithelium with columnar cells bearing intestinal like microvilli on their surface and
tubuloalveolar glands extending into the lamina propria. It is involved in water and
electrolyte absorption.
The gallbladder is innervated by the hepatic branch of the anterior vagal nerve and by
the sympathetic nervous system via the coeliac plexus '. Fibres carried in the right
phrenic nerve may also be distributed to the gallbladder via the hepatic plexus.
Autonomic plexuses are found in both the muscular and submucosal layers; and
parasympathetic ganglia, predominantly in the body and fundus, have been identified
within these plexuses. These intramural plexi receive input from the vagus nerve and
the sympathetic nervous system.
1.2.2 Physiology
Gallbladder filling is determined by the rate of bile secretion from the liver and the
resistance to flow through the lower end of the bile duct produced by the SO. In
humans, the secretory pressure developed by the liver is 39 cm H2O with a common
2 • •bile duct pressure of 12 cm HbO . In the fasting state, the SO is tonicaly contracted to
a pressure of 12 to 15 cm H2O. In addition phasic contractions occur about six times
per minute. As the opening pressure of the cystic duct is approximately 8 cm H2O, the
pressure gradient at the SO inhibits flow into the duodenum and favours its entry into
the gallbladder.
Gallbladder motility is controlled by endocrine and neural mechanisms. Many peptides
function both as hormones and neurotranmitters.
(1) Hormonal factors
CCK is the primary hormone controlling gallbladder contraction. After meals, the
release of CCK from the I cell of the duodenal mucosa causes gallbladder contraction
and SO relaxation, thereby promoting bile flow into the duodenum '. CCK produced a
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dose dependent contraction of gallbladder muscle strips in vitro 3. In healthy
subjects, there was a direct relationships between physiological plasma CCK
concentrations and gallbladder emptying 4'5. Maximum gallbladder contraction was
obtained 15-30 minutes after exogenous administration of CCK, and 40 to 60
minutes after ingesting a fatty meal 6. The action of CCK on the gallbladder was
mediated by direct binding to a specific receptor which is an 85 to 95-kd protein 7
o
located on the smooth muscle cells of the gallbladder wall . Blockade of this
receptor by a specific CCK-A receptor antagonist, loxigumide, completely prevented
CCK-mediated gallbladder contraction in humans 9. In experiments on cats under
anaesthesia with ketamine, Behar and Biancani showed the presence of at least two
types of excitatory receptors for CCK in the feline gallbladder; one on postganglionic
cholinergic neurones, the other at the gallbladder smooth muscle i0'n. The effect of
CCK on the gallbladder was partially blocked by atropine; it also stimulated the
gallbladder smooth muscle directly as the atropine-resistant effect was unaltered by
complete denervation with tetrodotoxin 11. CCK has been identified within vagal
neurones of the gallbladder intramural plexus and may act as a parasympathetic
19 1
postsynaptic neurotransmitter or as a stimulator of acetylcholine release ' . The
neuronal and myogenic CCK receptors differ in their sensitivity to CCK. Takahashi
et al 14 elegantly demonstrated in an in vivo guinea pigs model that the gallbladder
response to physiological plasma levels of CCK could be markedly blunted by
atropine, whereas supraphysiological concentrations of CCK contracted the
gallbladder by an atropine-insensitive pathway. This suggests that at physiological
levels, the effect of CCK on the gallbladder is predominantly neural and cholinergic.
Therefore only a minor component of the endogenous CCK effect might be
myogenic.
The gallbladder does not simply fill passively during periods of fasting and then
discharge completely into the duodenum in response to a meal. Partial emptying and
refilling occur in association with the migrating motor complexes (MMCs) in the
duodenum in humans . The gallbladder periodically empties in relation to phase II of
the interdigestive motor activity in the duodenum lD, resulting in emptying of up to
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30% of that seen after a meal lb. This emptying could be abolished by cholinergic
blockade with atropine in healthy volunteers 17. These interdigestive contractions
serve to partially empty the gallbladder of viscid bile and this is thought to reduce
sludge and gallstone formation. The hormone motilin is not thought to be directly
responsible for gallbladder contraction because gallbladder contraction precedes rise in
17 19
plasma levels of this hormone in humans " .
Other gastrointestinal peptides and neurotransmitters have either cholecystokinetic
actions (direct and/or CCK potentiating) or cholecystostatic actions (direct and/or CCK
inhibiting). Gastrin belongs to the same family of peptides as CCK. It caused
gallbladder muscle contraction in some species, though much less potently than CCK 19
and not at all in man 20. Secretin, released from the upper gut by acid, had no intrinsic
effect on gallbladder muscle contraction although it potentiated CCK effects on the
gallbladder 21. In dogs neurotensin caused gallbladder contraction although its potency
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was much less than CCK ~ . In man, neurotensin caused gallbladder relaxation in vivo
but no effect was seen in vitro Pancreatic polypeptide caused relaxation of the
gallbladder and decreased intraluminal pressure which encouraged refilling after
contraction 24. The concentration of pancreatic polypeptide remains elevated up to six
hours after meals. This suggests that the hormone could have a role in the regulation of
gallbladder filling. Vasoactive intestinal polypeptide inhibited the contractile response
of the gallbladder in vivo 2D. Somatostatin diminished hepatic bile secretion and was
also a potent inhibitor ofmeal or CCK induced gallbladder emptying in man26.
(2) Neural factors
Neural control of the gallbladder is mediated by intramural plexus that receive input
from the vagus, sympathetic nervous system and the intramural plexus of the
choledochoduodenal junction. This plexus contains cholinergic, adrenergic,
IT
serotonergic and peptidergic neurons . CCK and Vasoactive intestinal peptide have
19 ••
been identified in this plexus . Vagal activity contributes to normal gallbladder tone.
Direct cholinergic stimulation by bethanechol produced significant gallbladder
emptying and cholinergic blockade with atropine diminished the gallbladder
20
emptying responses to food and CCK 27-28. This effect of cholinergic blockade
90
appeared to be mediated by a selective muscarinic M2 receptor . However, the
effect of vagotomy upon gallbladder contraction is unclear. Human and animal
studies have shown that truncal vagotomy led to loss of gallbladder tone, gallbladder
distension and increased risk of gallstones formation 30. In contrast, several studies
showed increased gallbladder sensitivity to both endogenous and exogenous CCK in
vagotomised dogs 31 and humans 32. The physiologic role of sympathetic innervation
is also unclear. Administration of adrenaline, noradrenaline or isoproterenol
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produced no effect at physiologic doses but adrenergic agents relaxed the CCK
stimulated gallbladder l2.
(3) Other hormones and drugs
Women are twice as likely as men to develop gallstones and this may be due to
differences in sex hormones. Progesterone inhibits gallbladder contractions.
Gallbladder emptying is impaired in pregnancy and during the luteal phase of the
menstrual cycle j4. Apart from effects on gallbladder mucus production, several
prostaglandins have been shown to produce gallbladder contraction in vitro A
Indomethacin, a potent inhibitor of prostaglandin synthesis, relaxed the gallbladder and
this might account for its effectiveness as an analgesic for patients with biliary colic
36,37
Erythromycin, a motilin agonist, produced a dose-dependent emptying of the
gallbladder in normal volunteers and in patients with gallstones 38. Studies on cisapride
have produced conflicting results 39'40.
(4) Early gallbladder emptying
A paradox noted by other investigators is that the gallbladder starts to empty almost
immediately after ingestion of fatty meal41'42. it seems very unlikely that this occurs as
a consequence of nutrient induced CCK release from the small bowel since the stomach
does not start to empty for several minutes after ingestion. The mechanism for early
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gallbladder emptying contraction is unknown but this is discussed further in section
6.4.
1.3 Sphincter of Oddi
1.3.1 Anatomy
The pancreaticobiliary sphincter was first described by Glisson in 1654 4j but it was
named after Ruggero Oddi who characterised it extensively 44. He was the first person
to perform manometric study on the SO. Boyden later distinguished the different
parts of the SO in several species and in humans 4\
The right and left hepatic ducts join outside the liver, near the porta hepatis, to form the
common hepatic duct. Occasionaly, the right and left hepatic ducts do not join until the
cystic duct has joined the right hepatic duct; in that case there is no common hepatic
duct. The cystic duct connects the neck of the gallbladder to the common hepatic duct
to form the common bile duct. It usually enters the common hepatic duct directly but it
sometimes run parallel to or spirals around the common hepatic duct before entering it.
The common bile duct varies in length from 5 to 17 cm. Its diameter varies from 0.3
to 1.5 cm, and can become markedly distended by biliary obstruction. The common
bile duct contains scanty smooth muscle arranged in a circular fashion 46. It has a
fibroareolar coat. The lumen is lined by columnar epithelium that is continuous with
that of the gallbladder and the other extrahepatic bile ducts. It is divided into four
segments: supraduodenal, retroduodenal, pancreatic and intraduodenal 46. The
intraduodenal segment lies posterior and superior to the main pancreatic duct and is
about 2 cm long. A number of variations exist in the fusion and entrance into the
duodenum of the bile and pancreatic ducts 47. After running parallel for 0.2 to 1 cm,
the two ducts may join outside the duodenum, or they usually form a common channel
as they course through the duodenal wall to form the ampulla and terminate at the
papilla of Vater; in these cases, a single ostium is identified on the major duodenal
papilla during endoscopy. The papilla of Vater is a small, nipple-like protrusion from
the pancreatic border of the duodenum, usually at the junction of the second and third
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part. The papilla of Vater is rarely larger than 1 cm in diameter from endoscopic study
jo
m m
. In about 30% of cases, however, these ducts drain separately into the duodenum (in
which case there is no ampulla), or the ampulla is so short (<2 mm) that it is almost
non-existent. The bile and pancreatic ducts become narrower as they traverse the
papilla of Vater. The transampullary septum, the thin veil of tissue that separates the
terminal end of the bile duct, may be an important anatomic structure because it is
shared by the two structures as a common wall49. The intraduodenal segment of the
common bile duct and the ampulla of Vater are surrounded by a smooth muscle sheath.
This complex system of circular and longitudinal muscle is called the sphincter of Oddi
(SO).
The intrinsic muscle fibres of the SO differ from the musculature of the duodenum both
in embryologic development and in histologic features. The SO can be divided into
four sections. The sphincter choledochus surrounds the distal common bile duct just
prior to joining the pancreatic duct. The sphincter pancreaticus is a circular muscle
layer present at the terminus of the pancreatic duct. The muscles of the sphincter
choledocbus and the sphincter pancreaticus usually interlace in a figure-of-eight
fashion. The sheath of smooth muscle surrounding the ampulla is called the sphincter
ampullae; it is a continuation of sphincter choledochus. If there is no ampulla, the
distal sphincter is called the sphincter of the papilla. The mean extraduodenal length
of sphincter is estimated to be 5 mm (1 to 11 mm) and the mean intramural length to
be approximately 14 mm (7 to 22 mm). Thus the mean length of the sphincter is
around 19mm M'J. However, the physiologic sphincter as based on manometric study,
is significantly much shorter with an average length of 10 mm 51.
The human papillary complex passes through the duodenal wall at an acute angle. It is
likely that the duodenal wall in this area contributes to the pressure gradient that exists
within the papilla of Vater. A contraction of duodenal smooth muscle or a rise in the
intraduodenal pressure could, increase the transpapillary pressure and thereby prevent
the reflux of duodenal contents into the common bile duct and pancreas 52.
23
Histologically, the SO consists of a scanty layer of longitudinal smooth muscle and a
• • ST • •
prominent outer layer of circular muscle . Myenteric ganglia are present between
these muscle layers and abundant nerve bundles have been found overlying the
adventitia 54. Similar to the gallbladder, the SO is innervated by sympathetic nerves
from the coeliac ganglia via the splanchnic nerves which supply motor and inhibitory
fibres. Parasympathetic innervation is derived from the vagal nerves which supply
motor and sensory fibres. Catecholamines and other gastrointestinal peptides such as
galanin, vasoactive intestinal peptides, somatostatin and substance P have all been
identified in the neurons 55. However, the relation between the intrinsic myenteric
ganglia and extrinsic innervation remains unknown.
1.3.2 Physiology
The primary function of the SO is to control the delivery of bile and pancreatic juice
into the duodenum. The SO also diverts bile into the gallbladder and prevents reflux
of duodenal juice into the ducts.
The exact mechanism by which the SO regulates bile flow in response to feeding
remains controversial and the physiologic significance of the direction of phasic
contractions remains obscure. There is variation between species in the neural and
hormonal control of interdigestive and postprandial SO motility.
There is evidence that in herbivorous animals such as the prairie dog 36, American
opussum 57, and rabbit 58, the SO exhibits an excitatory response to CCK and
feeding. In these animals the SO is believed to actively pump bile into the
duodenum. In carnivorous animals such as dogs 39 and man, ingestion of a meal 60
and injection of CCK 61 produces a decrease in SO basal pressure with reduced
amplitude and frequency of phasic contractions. This facilitates the flow of bile into
the duodenum.
As in the gallbladder, the actions of CCK upon the SO are believed to be mediated
by myogenic and neural pathways ". CCK stimulated postganglionic nonadrenergic,
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noncholinergic inhibitory neurons to relax the SO and this was abolished by
tetrodotoxin in anaesthetised cats. CCK also caused SO contraction by stimulating
excitatory receptors on the smooth muscle; and this effect became apparent only after
complete denervation with tetrodotoxin. This suggests that CCK has a neurally
mediated, inhibitory effect that overrides a direct excitatory effect on the SO smooth
muscle 1 . This is supported by observation from experimental work on
anaesthetised prairie dogs that truncal vagotomy increased baseline resistance to bile
f\"\
flow and increased the frequency and amplitude of SO phasic contractions
The human SO, like the gallbladder, exhibits regular contractile activity during
passage of the migrating motor complex of the upper gastrointestinal tract. This was
studied by Worthley et al using a manometric catheter through the T-tube of patients
undergoing biliary tract surgery 60. Unlike the duodenum, the SO exhibited regular
phasic activity during phase I and contraction frequency increased during phase II of
the duodenal cycle. The SO contracted independently of the duodenum. During
phase III, the SO contractile frequency was similar to duodenal frequency and its
basal pressure increased. These findings suggest that during this phase, bile flow
from the bile duct into duodenum is retarded. This is consistent with the finding that
gallbladder contraction reached its peak during phase II, just before phase III of the
duodenal cycle 15'16. These interdigestive cyclic contractions may be mediated
through the action ofmotilin.
Phasic contractions of the SO may be antegrade, retrograde or simultaneous. In
humans, it appears that phasic contractions have a dual role. Antegrade contractions
help to expel small volumes of bile into the duodenum and this prevents reflux of
duodenal contents into the biliary tree. The simultaneous and retrograde waves
create resistance to flow and the pressure gradient helps to cause influx of bile into
the gallbladder, particularly during the interdigestive phase of gallbladder filling.
These forceful contractions are thought to help to prevent reflux of duodenal contents
into the biliary tree. Feeding causes a decrease in SO motility thereby facilitating the
flow of bile into duodenum. It therefore appears that in herbivorous animals, the SO
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acts like a pump whereas in carnivorous species like man, the SO acts as a variable
resistor in controlling bile flow64"66.
In both the cat and opossum, there are nerve trunks that connect the gallbladder and
SO 67'68. These nerve trunks connect groups of ganglia found at the junction of cystic
duct and bile duct, in the gallbladder wall and the SO. Examination of human
gallbladders and SO have confirmed the presence of similar ganglia and nerve plexus
50. In man, distension of the gallbladder inhibited the amplitude of SO phasic
contraction 69. In cats, this "cholecysto-sphincteric" response could be abolished by
interruption of the neural connections between the gallbladder and SO with injection
of tetrodotoxin or local anaesthetic agent at the junction between the cystic and
common bile duct 70. This suggests that these connecting nerve trunks could be
similar to the CCK responsive inhibitory neurones for the SO. It is not clear whether
there is a "pacemaker" controlling SO relaxation.
1.4 Choieevstokinin
1.4.1 Historical
In 1928, Ivy and Goldberg demonstrated that extracts of small intestinal mucosa
caused contraction of the gallbladder; they called the active material CCK 71. In
1943 Harper and Raper extracted a potent stimulant of pancreatic secretion from
small bowel mucosa which they named pancreozymin 72. However, it was not until
1960's that it became feasible to purify and characterise CCK through the meticulous
work by Mutt and Jorpes 73'74. They discovered that CCK was a sulphated
tritiscontapeptide amide which possessed gallbladder and pancreatic stimulatory
activity and showed that CCK and pancreozymin were a single hormone. Because
CCK was discovered first, it became conventional to refer to the polypeptide as
CCK. It is now known that CCK has multiple actions. It acts as both a hormone and




CCK is expressed in endocrine cells in the gut and in neurones of the brain and gut
75. CCK occurs in several bioactive forms and the biogenesis of CCK involves
modifications of pro-CCK. the precursor, resulting in extensive molecular
heterogeneity. The original material isolated was CCK-33, subsequently CCK-8,
CCK-22, CCK-39 and CCK-58 were identified. These are all derived from pro-CCK
and are all sulphated on the tyrosine residue at position 7 from the carboxyl-terminal
76. CCK shares a common five amino acids sequence at the carboxyl-terminus with
gastrin (Figure 1.1); the biological activity ofCCK is contained in the eight carboxyl-
terminus residue, the sulphation on the tyrosine being an absolute requirement. Only
50% of gastrin is in the sulphated tyrosine form which is located at position 6.
Desulphation or shifting the tyrosine residue from this position abolishes CCK
activity. CCK33 and CCK39 are the major circulating molecular forms constituting
77 • • • •
up to 55% . Basal plasma CCK concentration, measured by radioimmunoassay, is
approximately 2.6 pmol/1 and ingestion of a low and medium fat meal induces a rise
• • • 7R
in plasma CCK concentration to 6.1 pmol/1 within 15 minutes ; fatty meal is known
to increase CCK concentration to approximately 15pmol/l at 60 minute 79. CCK is
on
almost completely metabolised on first passage through the liver and metabolites
81 • • •
are excreted through the kidney . The plasma half life of CCK is about 2.5 minutes
in man and the dog 81.
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Figure 1.1 Molecular structure of porcine CCK. The filled circles indicate C-
terminal pentapeptide sequences (29-33) that is homologous with C-terminus gastrin
(Adapted from Rehfeld a\
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1.4.3 Regulation of cholecystokinin release
(1) Stimulants of cholecystokinin release
CCK is located in the I-cell within the mucosal glands of the proximal small
intestine. These cells are most numerous in the duodenum, and become less frequent
distally. CCK is also found in the neurones of the central and peripheral nervous
system.
In man, plasma CCK concentrations are increased after ingestion of a meal and
during infusion of bombesin 83-85. Fat and protein are the most potent stimuli 83'86.
Intraduodenal infusion of saline does not stimulate CCK release 84. The role of
carbohydrate in stimulating CCK release is rather controversial; Liddle et al 78
demonstrated that carbohydrate could induce release of CCK; several other studies
produced conflicting results 8j'87. Triglycerides required hydrolysis and dispersion of
fatty acids into micelles to become effective stimulants 88. Inactivation of lipase
activity in the upper small intestine by the lipase specific inhibitor
tetrahydrolipostatin inhibited CCK release in response to unhydrolysed fat . In
rats, intact protein but not amino acids, stimulated the release of cholecystokinin and
pancreatic exocrine secretion 89'90. In man, protein also required to be digested
before it stimulated CCK release 91. Intraduodenal perfusion of camostate at a
concentration that inhibited proteolytic activity, significantly lowered
protein-stimulated, but not amino acid stimulated, plasma CCK, gallbladder
emptying, and pancreatic enzyme output. That adequate protein digestion and
lipolysis is necessary for CCK release, is consistent with observations in patients
with exocrine pancreatic insufficiency in whom supplementation of pancreatic
• • Q9
enzyme restored impaired postprandial release of CCK and gallbladder motility .
CCK release and gallbladder contraction after a fatty meal was impaired in patients
with coeliac disease although this could be normalised by ingestion of pre-digested
meals 93'94.
Little CCK is released during the cephalic 95'96 or the gastric phase of digestion 87.
CCK was released in anaesthetised dogs by electrically stimulating the vagus nerves
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97, whilst sham feeding 96 and insulin hypoglycaemia as vagal stimulation in man did
not consistently lead to CCK release . Vagotomy in man did not influence the
release of CCK but increased the sensitivity of gallbladder smooth muscle to this
•39 ...
hormone . It therefore appears that only intestinal stimulation results in significant
CCK release.
(2) Feedback inhibition
In 1943 Thomas and Crider showed that peptone, soap or hydrochloric acid caused
less bile secretion when given in the presence of sodium taurocholate to the canine
intestine than when given alone, suggesting that bile had an inhibitory effect on
pancreatic secretion Malagelada and co-workers confirmed this findings three
decades later demonstrating in healthy volunteers that bile acids inhibited gallbladder
contraction and pancreatic enzyme secretion stimulated by luminal fatty acids and
amino acids I00'101. Cholestyramine, a bile acids sequestrator, markedly increased
amino acids stimulated 102 and bombesin-stimulated 84 CCK release and pancreatic
x • 102
protein secretion
In rats, negative feedback regulation of CCK release is mainly mediated by
intraluminal protease activity 103'104. In contrast, considerable controversy exists
whether such a regulatory mechanism operates in man. Slaff et al 105 and Owyang et
al 106'107 demonstrated in man that exogenous trypsin suppressed CCK release and
pancreatic enzyme secretion stimulated by amino acids or fatty acids. However,
other studies in man failed to confirm such a feedback mechanism 108-110.
Administration of the protease inhibitor camostate did not affect bombesin stimulated
plasma CCK concentration or gallbladder volumes. There could be several
explanations for the discordant findings. Firstly, an inhibitor-resistant trypsin may
be present in human pancreatic juices and secondly, it may be necessary to inhibit all
three pancreatic endopeptidases because all of them have inhibitory effect on CCK
release. Thirdly, it may be necessary to provide appropriate amino acids or fatty
acids as stimulus before protease inhibition can be demonstrated. One recent study
using a sensitive and specific CCK radioimmunoassay showed that intraduodenal
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camostate did not augment CCK released by intraduodenal amino acids, albumin 91
and infusion of bombesin 84.
Dietary stimulation appears to be the most important factor regulating CCK release
under physiological conditions. The intensity of CCK release is controlled by CCK
expressing genes; intraduodenal administration of trypsin inhibitor significantly
increased CCK mRNA. In contrast, fasting was associated with a decrease of
duodenal CCK mRNA levels and this was restored rapidly by refeeding m. This
appeared to be a specific effect upon CCK genes as fasting and refeeding did not
produce any changes in either duodenal somatostatin or its mRNA concentration.
Other gut hormones such as somatostatin and bombesin, which are also modified by
diet, also affect CCK release. There is some evidence that PYY, an enterohormone
released from the distal small intestine and colon, may inhibit the release of CCK
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1.4.4 Cholecystokinin receptors
CCK exerts its effects through G protein-coupled seven transmembrane domain
receptors coupled to stimulation of phospholipase C 113. There are two receptors
subtypes. CCK-A receptors, characterised most extensively on pancreatic acinar cells
and named for their alimentary origin, and CCK-B(brain) receptors. Both forms
have now been described in both the gut and brain. CCK-A receptors have 1000-fold
higher affinity for sulphated CCK than for gastrin, whether sulphated or not 114.
CCK-B receptor is similar or identical to the peripheral gastrin receptor. CCK
shows different contractile responses in stomach, intestine and gallbladder which
could be attributed to the different cellular location of CCK receptors. In the
intestine, the response is largely mediated by neural CCK receptors and depends also
on release of acetylcholine from cholinergic neurons. In the fundus of the stomach
and gallbladder, the response is largely mediated by smooth muscle receptors 115.
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1.4.5 Regulation of gastric acid secretion and motility by cholecystokinin
CCK has been implicated in the control of gastric acid secretion. The effects of CCK
on gastric acid secretion are rather complex and were poorly understood until
recently. Exogenous CCK or its analogue, caerulein, administered alone in fasted
human caused weak stimulation of gastric acid secretion but inhibited
pentagastrin-induced acid secretion 115. The parietal and histamine-producing cells
express a CCK-B/gastrin receptor that mediates gastrin-induced gastric acid
secretion. The structural similarity between CCK and gastrin and their ability to bind
equipotently to this receptor as agonists suggests that both hormones can stimulate
gastric acid secretion "7. The inhibitory effect on acid secretion is postulated to be
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mediated through the CCK-A receptor located on somatostatin-producing cells
Loxiglumide, a specific CCK-A receptor antagonist, increased both gastric acid
secretion and plasma gastrin in response to a peptone meal and ordinary meal in a
group of healthy volunteers'1,120. Loxiglumide also further enhanced acid secretion
induced by caerulein/CCK-8 and gastrin releasing peptide 119,l2°. However,
loxiglumide failed to affect basal gastric acid outputs and plasma gastrin
concentrations 119-121 The findings from these studies suggest that CCK does not
play any role in the control of basal gastric secretion but post-prandial CCK release
has a tonic inhibitory influence upon b oth gastric acid output and gastrin release via
the CCK-A receptor located on somatostatin releasing D cells 118. It is postulated that
CCK stimulates the paracrine secretion of somatostatin which inhibits acid output
from parietal cells and gastrin released from G-cells, and this inhibition can override
a direct stimulation of acid secretion via CCK-B/gastrin receptors on parietal cells.
In addition to its effect on gastric acid secretion, CCK also has regulatory effects on
gastric motility. Meyer et al showed that loxiglumide reduced colonic transit time
199
and gastric emptying of liquid meal in healthy volunteers . Fried et al later
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reconfirmed that physiological concentration of CCK inhibited gastric emptying
It is possible that CCK principally controls liquid emptying since the CCK antagonist
L364,718 had no effect upon gastric emptying of solid-liquid meal I24.
Physiological doses of CCK infusion were also known to stimulate pancreatic
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secretion (see 1.4.7). Therefore CCK acts as a common regulator for gastric
emptying and pancreatic secretions so as to optimise the ratio of nutrients entering
the upper small intestine to pancreatic digestive juices. Little is known about the
mechanisms by which CCK regulates gastric motility. It may act directly through
spec! fic receptors on smooth muscle cells or through the release of other substances.
• 118
As eluded to earlier, CCK is a potent releaser of somatostatin from antral mucosa ,
a peptide also known for its inhibitory actions on gastrointestinal motility. It may
also act as a neurotransmitter as the inhibitory effect of CCK on gastric emptying
could be prevented by destroying capsaicin-sensitive vagal afferents in rats 1 5.
1.4.6 Regulation of pancreatic secretion and growth by cholecystokinin
(1) Secretion
In contrast to the complete blockade of CCK-induced gallbladder contraction,
loxiglumide only reduced CCK-induced postprandial pancreatic secretion by 50%
l26. The inability of the CCK antagonists to completely inhibit postprandial exocrine
pancreatic secretion of enzymes suggests that other hormones and neural
mechanisms are also involved in the regulation of meal-stimulated pancreatic
secretion. CCK was found to be a strong stimulant of pancreatic enzyme secretion
• /-• • • 197
but was probably not the major regulator of water and bicarbonate secretion . It
produced marked augmentation of bicarbonate secretion in man when combined with
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secretin
Recent data suggests that CCK stimulates pancreatic secretion not only through
specific receptors at the acinar cells but also through interaction with the cholinergic
system. In vitro studies with dispersed pancreatic acini showed that CCK-stimulated
amylase release was insensitive to atropine or tedrodotoxin, indicating direct action
190 • •
on pancreatic acini . In vivo studies in man showed that pancreatic secretion
stimulated by CCK could be blocked by atropine, suggesting action via a cholinergic
pathways 130'131. Atropine and loxiglumide both inhibited pancreatic secretion but
inhibition by atropine was more pronounced at physiological than at
supraphysiological CCK doses 13'. This is consistent with observations reported by
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Malagelada that the secretory response induced by small but not high doses of CCK
132
was reduced by vagotomy . Using an in vivo rat model, Owyang et al
demonstrated that physiological doses of CCK stimulated the vagal afferent pathway
1 77
. Therefore the action ofCCK on pancreatic secretion is modulated by interactions
of its action directly on acinar cells and cholinergic neurones.
2) Pancreatic growth
In the rat repeated injection of CCK analogues caused marked increases in pancreatic
weight due to hypertrophy and hyperplasia 134. It is also known that feeding of
trypsin inhibitors and pancreaticobiliary diversion stimulated pancreatic growth
1 7S it/:
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. Such inhibition or diversion of proteolytic enzymes increased plasma
concentration of CCK. The role of CCK as a cancer growth promoter is less clear.
CCK was shown to have trophic effects upon cancer cell lines derived from
pancreatic exocrine glands or ducts 137. Despite the marked hypertrophy and
hyperplasia induced by CCK. no neoplastic nodule was observed in rats exposed to
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trypsin inhibitors
1.4.7 Regulation of intestinal motility
Ingestion of a fatty meal lowered the basal lower oesophageal sphincter pressure.
Although the mechanism for this observation remains unclear, CCK released by fatty
meal could be responsible I38. Infusion of CCK induced a dose-dependent reduction
in lower oesophageal sphincter pressure 139,140 but this reduction in pressure has only
been consistently shown with supraphysiological doses of CCK 141,142. The role of
CCK-induced lower oesophageal sphincter relaxation in gastro-oesophageal reflux
after a fatty meal in healthy subjects is therefore probably of minor importance.
CCK analogues increased transit of contrast material through the human small
intestine I4j. CCK increased the frequency of electrical spike potential in human
colon in vitro l44. The colonic electrical pattern typical of the gastrocolonic response
to a fat meal could be reproduced by intravenous CCK.
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1.4.8 Regulation of blood flow
CCK caused vasodilation in upper small intestine, and increased blood flow in the
liver of dogs 144 and pancreatic microcirculation 145. Whether the CCK induced
increases in capillary blood flow is a direct effect of CCK or is a result of a paracrine
operating system remains to be elucidated.
1.4.9 Effects of cholecystokinin on appetite
High concentrations ofCCK are present in the cerebral cortex and limbic system and
is colocalised with dopamine in some neurones 146. CCK has been shown to affect
various responses in central nervous system including satiety and anxiety.
CCK has been proposed as a major mediator of the satiety response that leads to
cessation of feeding when food is placed in the stomach or intestine. Physiological,
post-prandial CCK concentrations significantly increased satiety and decreased food
intake in humans l47. Intraduodenal infusion of fat decreased food intake when
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compared with saline infusion; this effect could be prevented by loxiglumide . The
mechanisms underlying the satiety effects of CCK are unclear; there could be
paracrine or neurotransmitter effects. Subdiaphragmatic vagotomy blocked this
effect, suggesting that it was peripherally mediated 149.
1.4.10 Effects of cholecystokinin on anxiety
Intravenous injection of CCK-4 provoked panic-like attacks in normal subjects and
this anxiogenic effects was most likely to be mediated centrally 15°. The receptor
responsible is probably the CCK-B receptor because activation of this receptor
caused anxiogenic-like effect in rats, whereas receptor blockade alleviated anxiety
15'. The CCK-B receptor is present throughout the brain and is similar to the
peripheral gastrin receptor. It is interesting to note that pentagastrin injection could
provoke panic attacks 15'.
1.4.11 Measurement of cholecystokinin
(1) Radioimmunoassay
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Many problems in the developments of a sensitive and specific radioimmunoassay
for CCK could be related to the structure of the peptide, which displays remarkable
similarities to gastrin in their active moeities; sharing an identical amidated
pentapeptide at the carboxyl end (figure 1.1). Since the carboxyl-terminal
pentapeptide is highly immunogenic, this similarity caused considerable problems in
raising specific antisera directed towards biologically active molecular forms ofCCK
as antibodies raised towards this region often had cross reactivity with gastrin. On
the other hand, antibodies directed towards the mid portion or ammo-terminal
antigenic determinant may be species specific and may fail to measure small CCK
• 89
fragments such as CCK-8 that contains the biologically active carboxyl-terminal .
A sensitive and specific assay should measure sulphated CCK-8 and larger sulphated
CCKs with equimolar potency without reacting with gastrin. As shown in figure 1.1,
such an assay should be specific for the amino-terminal part of CCK-8 which
contains the sulphated tyrosine residue. Recently, antibodies have been raised that
have high specificity for this biologically active sulphated C-terminal region of CCK
7 C OO _ # t
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. A further difficulty related to preparation of a tracer which recognised
antibodies directed against che biologically active part of the CCK sequence. It was
difficult to perform oxidative iodination of this tracer without damaging the
biological activity. This was overcome by non-oxidative coupling of
12T-hvdroxyphenylpropionic acid-succinimide ester by a modification of the
Bolton-Hunter procedure to the CCK-33 and latterly, CCK-8.
Heterogeneity is a particular difficulty for CCK since CCK antibodies may possess
different affinities for the various molecular forms of CCK circulating in plasma
(CCK-8, CCK-33, CCK-39 and CCK-58). This may introduce underestimation or
overestimation ofCCK 75.
Plasma CCK concentrations measured in the circulation by sensitive and specific




The basic unit for biological measurement of CCK is the Ivy Dog Unit, defined as
the amount of material that produces optimal contraction of the canine gallbladder
after rapid intravenous injection. The standard method for bioassay of natural CCK
is contraction of in situ guinea pig gallbladder. In vitro bioassays have been
developed for estimation of CCK activity in human serum. Marshall et al developed
a method of using rabbit gallbladder that were first exposed to normal serum and
CCK-like activity was measured by contractility I53. There are noncholecystokinin
peptides that cause gallbladder contraction; therefore bioassay of this type tends to
over estimate CCK concentrations.
Liddle et al developed a novel method ofCCK bioassay by utilising amylase released
from pancreatic acini78. Plasma is extracted, concentrated and incubated with acini.
Gastrin does not interfere significantly with the assay; no other CCK-like bioactivity
has so far been identified.
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CHAPTER TWO
NITRIC OXIDE AND THE BILIARY SYSTEM
2.1 Discovery of nitric oxide
The striking inability of blood vessels to respond to vasodilating substances in the
absence of endothelium was resolved by the discovery of an "endothelium-derived
relaxing factor" that subsequently was shown to be identical to nitric oxide (NO) in
1987 154'15\ NO is the molecule responsible for the stimulation of guanylate cyclase
in a number of tissues including the brain and is also a cytotoxic factor released by
activated macrophages. NO is synthesized from the amino acid, L-arginine, by a
family of enzymes named NO synthase. The L-arginine : NO pathway has also been
identified in many other tissues, including platelets, adrenal glands, hepatocytes,
Kupffer cells, the lung and several cell lines. NO has a half-life of less than 10
seconds because it is rapidly oxidised to inorganic nitrite and nitrate. NO is also
destroyed by superoxide anion. Superoxide dismutase protects NO from breakdown
by superoxide anion l36'157. NO binds to oxyhaemoglobin and other haem-containing
proteins; its biologic actions are rapidly terminated by binding to oxyhaemoglobin
158,159
2.2 Actions of nitric oxide
2.2.1 Cardiovascular system
Vascular endothelial cells synthesize NO enzymatically from the terminal guanidine
nitrogen atom of L-arginine by the enzyme nitric oxide synthase (NOS), with
L-citrulline as the coproduct 160. The enzyme is constitutive, calcium- and
calmodulin dependent, and releases picomoles of nitric oxide in response to
stimulation 161. This reaction is specific, as a number of analogues of L-arginine,
including its D enantiomer, are not substrates. One analogue, the methylated
L-arginine analogue NG-monomethyl-L-arginine (L-NMMA), inhibits this synthesis
in a dose-dependent and enantiometrically specific manner. NO formed by
endothelium diffuses to nearby smooth muscle cells, in which it binds to ferrous iron
in the haem prosthetic group of the soluble guanylate cyclase (sGC), resulting in
enhanced synthesis of cyclic GMP from guanosine triphosphate (GTP). This
increase in cyclic GMP in the smooth muscle cells lead to their relaxation
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L-NMMA induced direct vasoconstriction in the brachial artery and attenuated
vasodilatation induced by bradykinin and acetylcholine 163, whereas it had no such
effect on the unstimulated hand veins. This suggests the arterial side of the
circulation has a continuous release of NO that maintains vasodilator tone.
L-NMMA constricted vascular beds and produced a hypertensive response in healthy
humans 164. The vaso-constrictor properties of L-NMMA is entirely
endothelium-dependent and results from the inhibition of the endogenous
vasodilator mechanism, the L-arginine : nitric oxide pathway. In rings of
atherosclerotic arteries as compared with rings of normal arteries, the
endothelium-dependent relaxation was decreased and the responses to
vasoconstrictors were often enhanced 165.
Platelets generate NO which inhibits platelet aggregation and adhesion by a
mechanism dependent on cyclic GMP I66. Aggregation induced by collagen is
accompanied by an increase in intraplatelet levels of cyclic GMP but not
adenosine-3',5'-cyclic monophosphate (cAMP). L-NMMA inhibits this increase in
cGMP and enhances aggregation.
A calcium-independent isoform of NOS can be induced in vessel walls by cytokines
and by endotoxin lipopolysaccharides, which act through the release of cytokines.
This induction occurs in endothelial and smooth muscle cells of vessels and the
myocardium. This leads to vascular relaxation that is resistant to vasoconstrictors
but can be prevented by NOS inhibitors and glucocorticoids. NO released by this
inducible NOS accounts for the vasodilation and hypotension characteristics of septic
shock as well as the hypotension induced by cytokine therapy in patients with cancer
/• | Q
. In patients with septic shock, low doses of N -monomethyl-L-arginine has been
shown to reverse the hypotension associated with septic shock 167.
2.2.2 Respiratory system
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Inhaled NO selectively dilates pulmonary vasculature and may protect against adult
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respiratory distress syndrome . It may be useful in patients with pulmonary
hypertension which has been found to be associated with diminished expression of
endothelial NOS I69. It is postulated that decreased expression of NOS may
contribute to the excessive growth of the tunica media observed in this disease.
2.2.3 Immunological system
The activation of macrophages by lipopolysaccharide and interferon gamma, results
in induction of the calcium-independent NOS. This induction, which is inhibited by
glucocorticoids, results in the sustained production of NO, which diffuses to target
cells such as tumour cells, bacteria, fungi, and helminths 17°. In these cells NO
combines with iron-sulphur centres in key enzymes of mitochondrial respiratory
cycle and pathway for DNA synthesis. These enzymes are subsequently inhibited
and result in cell death 171.
Increasing evidence indicates that NO may play a part in acute and chronic
inflammation. Nitrite concentrations in plasma and synovial fluid were increased in
patients with rheumatoid arthritis and osteoarthritis 172. Treatment with inhibitors of
NOS reduced the degree of inflammation in rats with acute inflammation 173 or
adjuvant arthritis I74, whereas L-arginine enhanced it. Increased urinary nitrate
excretion was observed in human subjects with diarrhoea and fever 175. The colonic
synthesis of nitric oxide was increased in patients with ulcerative colitis 176 and
inhibitors ofNOS ameliorated experimentally induced chronic ileitis 177.
The origin of NO in the inflammatory process is unclear, but it could come from
blood vessels, neutrophils and macrophages. NO may interact with oxygen-derived
radicals to generate molecules that could enhance its cytotoxicity 163. There are
reports suggesting that inhibitors of NOS 164,178 and NO donors 179 protect against
some forms of injury. This is probably due to the dual nature of NO, which is
cytotoxic and a vasodilator with potentially protective properties. At present, the
biological significance of NO production by inflammatory cells remains unclear but
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is likely to be involved in vasodilation, formation of oedema, modulation of sensory
nerve endings and tissue cytotoxicity. The release of NO may be a mechanism for
controlling the levels of O2". NO and O2" are known to interact rapidly to form the
peroxynitrite anion, which decomposes once protonated into potent oxidants OH and
NO2 18°. OH and NO2 oxidises sulphydryl groups and react with metal ions 181. It
has been shown that exposure of colonic mucosa to peroxynitrite results in
significant tissue injury 182. It has been suggested that the protective action of
superoxide dismutase in ischaemic tissue may be due in part to the prevention of the
formation of peroxynitrite and hence of these highly toxic radicals. However, at
present, there is no evidence for the formation of the peroxynitrite radical or its
decomposition into OH and NO2 in vivo, and therefore it remains to be established
whether the interaction between NO and O2" leads to an increased toxicity or is a
neutralizing mechanism for two toxic radicals.
2.2.4 Nervous system
(1) Central nervous system. Neurotransmission by agents such as acetylcholine,
glutamate and glycine has long been known to be associated with elevated cyclic
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GMP levels in the brain and particularly in the cerebellum . In 1982, the
endogenous activator of the soluble guanylate cyclase in the brain was identified as
L-arginine 184. Addition of L-arginine to rat synaptosomal cytosol in the presence of
NADPH as a cofactor, resulted in the formation of NO and citrulline and was
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accompanied by stimulation of soluble guanylate cyclase . Both of these processes
were inhibited by haemoglobin and L-NMMA. These data shows that the rat brain
possesses NOS which is Ca2+ dependent.
Cytosolic preparations of different brain regions showed that the highest
concentration of NOS was present in the cerebellum, followed by the hypothalamus
and midbrain, striatum, and hippocampus, with the lowest activity found in the
medulla oblongata 186. Histochemical studies using antibodies to NOS have shown it
to occur widely in the central nervous system, primarily in neurons and also in
vascular endothelium, with no glial localisation ,87. The biological function of
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L-arginine : NO in the brain remains to be elucidated. It is possible that NO is
involved in the short term effects of excitatory amino acids as well as in their
1 RR
long-term effects on brain development, learning and memory . It may also play a
role in the pathology of the central nervous system. Localisation of NOS
corresponds closely with that of NADPH diaphorase in both the brain and the
peripheral nervous system l89. NADPH neurons are selectively resistant to
degeneration in conditions such as stroke, Huntington's chorea, Alzheimer's disease
and in animals with cerebral ischaemia. Thus, neurones that release NO may be
resistant to its cytotoxic actions. Microglial cells, which are of
monocyte-macrophage lineage can express the inducible form of NOS 19°. These
cells have been implicated in the pathogenesis of diseases such as multiple sclerosis,
Alzheimer's disease, Parkinson's disease and the dementia of Acquired Immune
Deficiency Syndrome 191.
(2) Peripheral nervous system.
NO may contribute to sensory transmission and may also be the transmitter or
modulator in nonadrenergic noncholinergic (NANC) nerves in the gastrointestinal
tract (see 2.2.6). It is also responsible for the relaxation of the corpus cavernosum
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and thus penile erection in human . Immunohistochemical evidence of nerves
1QR
containing NO has been found in human penile tissue . NO also contributes to the
NANC vasodilatation and relaxation of human tracheal muscle 194. There is therefore
a widespread system of nerves throughout the body that use NO as a neurotransmitter
and there seems to be NO-dependent dilator tone that is crucial to the physiologic
function of these organs.
2.2.5 Nitric oxide and the endocrine system
NADPH and Ca" -dependent NOS has been identified and characterised in both
cortex and medulla of the adrenal gland 195. The functional importance of this
L-arginine : NO pathway in regulating adrenal cortex and medulla function is not
clear. cGMP has been implicated in both catecholamine secretion 196 and
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steroidogenesis I97. Rat mast cells have also been shown to produce an NO-like
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substance that modulated the release of histamine
2.2.6 Gastrointestinal systems
Present evidence indicates that NO mediates relaxation of the muscularis externa and
may play an important role in gastrointestinal mucosal blood flow, mucosal
protection, haemodynamic responses to liver disease, regulation of hepatocyte
function and mediation of hepatoxicity.
(1) Nitric oxide and neural inhibition of gastrointestinal motility.
The identity of the nonadrenergic noncholinergic (NANC) inhibitory
neurotransmitter that mediates smooth muscle relaxation remained unclear till
recently. Adenosine triphosphate and vasoactive intestinal peptide have been
proposed as the neurotransmitter but in many gastrointestinal smooth muscle
preparations, neither substance appears to be involved 199,200. In the early 1980's,
studies by Gillespie et al, demonstrated that a nonpurinergic, nonpeptidergic
neurotransmitter was involved in NANC neurotransmission in rodent and bovine
genitalia-associated smooth muscles. It was subsequently shown that NO mimicked
NANC relaxation, blockers of NO synthesis inhibited this effect and L-arginine
reversed this inhibition in the rat anococcygeus muscle 20I>202. Bult et al provided
evidence that NO was released on stimulation of NANC nerves in the canine
ileocolonic junction 203.
NANC neurotransmission has been extensively studied in the smooth muscle from
the lower oesophageal sphincter, gastric fundus, gallbladder, SO, ileocolonic junction
and internal anal sphincter.
(2) Lower oesophageal junction.
The lower oesophageal sphincter provides a physiological barrier that prevents reflux
of gastric contents into the oesophagus. Stimulation of NANC nerves produced
relaxation of the lower oesophageal sphincter and contraction of circular smooth
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muscle 204. Electrical stimulation produced a frequency dependent relaxation of
lower oesophageal sphincter that was accompanied by an increase in cyclic GMP in
human (maximum relaxation at 8.0 Hz with a range of 1 Hz to 10 Hz, 1.0 msec, 65v)
and opussum (10Hz, 1.0 msec, 40 v) . The electrically induced relaxation
could be abolished by tetrodotoxin but was unaffected by atropine and guanithidine
indicating the relaxation responses are NANC in origin. Furthermore, the NANC
induced relaxation was inhibited by the NOS inhibitor, L-A-nitroarginine
(L-NOARG) 207. NOS activity, determined by the transformation of 14C-L-arginine
into I4C-citrulline, was detected in healthy human oesophageal tissue homogenates
but reduced in patients with achalasia 208. However, NOS activity could also be
detected in tissue homogenate of smooth muscle and striated muscle segments 209.
Immunohistochemical staining of human oesophageal tissue with polyclonal
antibody raised against a peptide sequence of rat brain NOS confirmed the presence
ofNOS in the myenteric plexus of the gastro-oesophageal junction of healthy control
but reduced in patients with achalasia 208 and congenital oesophageal stenosis 21°.
NO was released upon stimulation (10Hz, 1.0 msec, 30 v) of intrinsic nerves of the
lower oesophageal sphincter as detected by a chemiluminescence NO analyser 2n.
The NOS identified required NADPH, Ca2+, calmodulin activity and could be
inhibited by L-NNA ~ . Injection of aqueous solution ofNO gas has been reported
to relax gastro-oesophageal sphincter in patients with achalasia212.
(3) Gastric smooth muscle
The fundus of the stomach actively dilated to accomodate the intake of food with
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little increase in intragastric pressure . This relaxation occurred predominantly in
the proximal stomach and was more pronounced after a liquid meal. This response
was neurally mediated but the nerves involved were neither adrenergic nor
cholinergic. Desai et al 214 demonstrated that this adaptive relaxation was mediated
by NANC and the neurotransmitter was indistinguishable from NO. Incubation of
guinea-pig stomach with tetrodotoxin abolished the response which was not
abolished by incubation with guanethidine and atropine. Incubation with L-NMMA
abolished this adaptive relaxation. L-arginine reduced the amplitude of spontaneous
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contraction of canine antral smooth muscle in vitro and sodium nitroprusside, a NO
donor, hyperpolarised resting membrane potential and decreased contractile
responses to acetylcholine 2l3. In contrast, L-NMMA augmented acetylcholine
induced contraction. NOS has been identified through immunohistochemistry
techniques in the myenteric neurones of gastrointestinal tract 187. Konturek et ai
demonstrated that sublingual glyceryl trinitrate (a NO donor) inhibited gastric
emptying and antral motility after liquid meals in healthy volunteers 216. The
involvement of NO in the regulation of gastric emptying in human was subsequently
confirmed by the same investigators with the infusion of L-NMMA. L-NMMA
caused a significant reduction of the gastric emptying half-time which could be
completely reversed by addition of L-arginine to the L-NMMA infusion 217. The
increase of gastric emptying half time was thought to be due to the suppression of
receptive relaxation of the proximal stomach.
(4) Gastric mucosal blood flow and secretion
Both local administration of acetylcholine and vagal stimulation induced
• 91^ •
vasodilatation of gastric mucosa " . There is evidence implicating endogenous NO
in modulating the resting gastric microcirculation. Studies using hydrogen gas
910 990
clearance , radio labelled microspheres technique and laser Doppler flowmetry
221 have demonstrated that intravenous administration of L-NMMA reduced resting
gastric mucosal blood flow. Intra-arterial infusion of glyceryltrinitrate induced
vasodilatation in the mucosal microcirculation 222. The mucosal hyperaemia in rats
induced by intravenous pentagastrin was attenuated by pre-treatment with low dose
L-NMMA222. However, L-NMMA had no effect upon peak pentagastrin-induced
acid secretion, indicating an effect on the microcirculation independent of secretory
modulation.
NO may play an important role in gastric mucosal protection. Topical application of
either nitrosothiol S-nitroso-A-acetyl-penicillamine (SNAP), which spontaneously
liberates NO or isosorbide dinitrate to the rat gastric mucosa in vivo augmented the
thickness of the overlying mucus gel 223. no may interact with other sensory
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neuropeptides in the regulation of gastric mucosal integrity. Administration of
L-NMMA induced gastric mucosal injury in rats pre-treated with indomethacin and
two weeks of neurotoxic dose of capsaicin to deplete sensory neuropeptides 224. The
stimulation of afferent neurons by lower dose of intragastric capsaicin protected the
gastric mucosa against damage induced by ethanol 22i'226 and acidified aspirin 211.
This protection appeared to depend on the marked vasodilation elicited by capsaicin
in the gastric mucosal microcirculation. Capsaicin sensitive neurons contain a
number of vasoactive peptides, including substance P, VIP and calcitonin
gene-related peptide (CGRP). CGRP appears to be the major peptide released from
capsaicin sensitive neurons that is involved in mucosal vasodilation as CGRP
receptor antagonist (CGRP8-37) inhibited the hyperaemic response to capsaicin 228.
In ethanol-induced mucosal damage models in rats, CGRP8-37 dose dependently
attenuated the protective effect of CGRP and this effect could be reversed by
L-arginine. Protection by CGRP was not associated with increased prostaglandin
formation 229. These findings suggest that CGRP is an essential mediator of the
protection elicited by stimulation of capsaicin-sensitive neurons and the protective
effects of CGRP depends on the L-arginine : NO pathways.
Apart from stimulation of capsaicin sensitive neurons, pentagastrin has also been
reported to protect against ethanol-induced mucosal damage in rats 230. These
effects have demonstrated to involve capsaicin afferent neurons, CGRP and the
L-arginine:nitric oxide pathway 2jl. NOS activity was shown to be increased in
enterochromaffm-like cells associated with hypergastrinaemia produced by
omeprazole in rats 232.
NO can be formed intragastrically from nitrite and nitrate in swallowed saliva and
from nitrate rich containing food such as lettuce. Intragastric production is probably
non-enzymatic, and requires an acidic environment as the amount of NO could be
reduced by pre-treatment with proton pump inhibitor in a group of healthy volunteers
~3j. Patients with duodenal ulcers had higher gastric antral and fundic inducible NOS
activity than normal subjects 234. NOS activity in Helicobacter pylori positive
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subjects with duodenal ulcers was two fold higher than Helicobacter pylori positive
normal subjects. The enhanced inducible NOS activity is probably derived from
inflammatory neutrophils and macrophages. NO combined with superoxide yielding
peroxynitrite which subsequently decomposed to highly toxic radicals OH and NO2
that might induce tissue injury 18°. NO might also delay proximal duodenal
contractions thus increasing the exposure of duodenal mucosa to gastric acid.
(5) Intestinal smooth muscle
NOS has been localised in the myenteric and deep muscular plexuses 187-23x236 and
NO participated in the regulation of small intestine myoelectric activity both in
mammalian and nonmammalian species 237. Infusion ofNOS inhibitors transformed
the postprandial motility into a fasting motor pattern. Moreover, the infusion of a
NO donor disrupted the MMC and generated an irregular spiking activity similar to
that observed during the postprandial state 237. NO induced NANC relaxation in
circular muscle strips of the canine terminal ileum, ileocolonic junction 238"239 and
colon 24°. Incubation with NOS inhibitor increased basal tension of the circular
muscle, which could be partly reversed by L-arginine. Intravenous injection of
lipopolysaccharide increased the constitutive and inducible forms of NOS in the
small intestine and accelerated gastrointestinal transit time. This rapid intestinal
transit time could be reversed by intravenous L-NMMA 241.
The internal anal sphincter is innervated by excitatory adrenergic innervation and
inhibitory NANC. The NANC nerves relaxed the IAS in response to rectal
distension, the recto-anal reflex 242>243. VIP has been proposed as a mediator of
NANC relaxations in this sphincter 243. However, none of the antagonists to VIP
studied so far is capable of completely blocking the effect of NANC stimulation,
implying that another NANC transmitter is involved. L-NNA reduced relaxation
induced by transmural field stimulation in isolated muscle strips of the opussum but
the inhibitory response to VIP was not affected by pre-treatment with L-NNA 244.
Electrical field stimulation (EFS) relaxed isolated strips of human internal anal
sphincters in the presence of atropine and guanethidine 24x246. Sodium nitroprusside,
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a NO donor, mimicked relaxation produced by EFS (frequency 10Hz, 10V, 0.5ms
duration) and this relaxation could be inhibited by NOS antagonists and
oxyhaemoglobin, a scavenger ofNO.
NO induces vasodilation in the rat isolated mesenteric vascular bed 247 and L-NMMA
increased tone and inhibited the vasodilation produced by acetylcholine in human
isolated omental arteries . Using a radiolabeled microspheres technique, L-NNA
has been shown to decrease blood flow in the duodenum, jejunum, caecum and colon
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Thus the evidence accumulated to date support strongly an involvement of NO in
NANC inhibitory neurotransmission. Conventional neurotransmitters such as
acetylcholine and noradrenaline are stored in membrane bound vesicles before their
release from presynaptic nerves, and they influence postsynaptic cells by interacting
with membrane bound receptors on the cell surface. NO is clearly not bound in
vesicles and challenges classic concepts of neurotransmission. Firstly, its receptor,
guanylate cyclase, is cytosolic rather than membrane bound. Secondly, NO is both
labile and very lipid soluble. It is thus unlikely to be packaged in membrane bound
vesicles before release. It has been suggested that NO is stored in a more stable
form, bound to another molecule such as cysteine, and there is some evidence
supporting this 240. Alternatively, NO can be produced on demand, and it is
conceivable that depolarisation makes calcium available for NOS activation within
the presynaptic neuron. The mechanism by which NO causes smooth muscle
relaxation has not been established. It is recognised that, by activating soluble
guanylate cyclase, NO increases synthesis of cGMP and this has been shown to
produce membrane hyperpolarisation in colonic smooth muscle . Such membrane
changes are the hallmark of NANC nerve mediated relaxation and are thought to
result from an increase in potassium conductance 240. The processes responsible for
electromechanical coupling include enhanced Ca2+ sequestration and reduced
sensitivity of the contractile apparatus to Ca2+.
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The high reactivity of NO with a variety of biologically relevant molecules and its
short half life under physiologic conditions have led several investigators to postulate
that NO-like activity may be stabilised in vivo 2-1"254. In particular, S-nitrosothiols
(RS-NO) formed from the nitrosation of SH groups of low molecular weight thiols
and proteins, are a class of relatively stable NO adducts that form under physiologic
conditions and retain smooth muscle inhibitory activity in gastrointestinal and
non-gastrointestinal tissue.
(6) Liver and pancreas
In the pancreas, L-NNA decreased canine pancreatic blood flow under resting
conditions and following stimulation with secretin and CCK and this led to decreased
pancreatic secretion 253.
Rat Kuppfer cells cocultured with hepatocytes and stimulated with lipopolysacharide
induced a significant suppression of hepatocytes total protein synthesis, but only
when L-arginine was present in the medium 2'6. This effect was associated with
formation of nitrite, nitrate and citrulline both in Kuppfer cells and the hepatocytes.
It was subsequently shown that the supernatant from activated Kuppfer cells induced
the formation ofNO in the hepatocytes, an effect that was blocked by L-NMMA 257.
These data have led to the suggestion that Kupffer cells activated by septic stimuli or
other inflammatory states respond by forming NO and by inducing NO formation in
neighbouring hepatocytes. A major effect of NO is cytotoxicity due to suppression
of hepatocyte protein synthesis. Induction of NO by endotoxin in hepatocytes has
been demonstrated in vivo 2iS. There is evidence that NO synthesis contributes to
vasodilatation in portal hypertensive cirrhotic rats 259 and renal failure 260.
2.3 Evidence for role of nitric oxide in the biliary system
2.3.1 Nitric oxide and the gallbladder
As in the stomach, the gallbladder accommodates changing volumes with little
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change in pressure . It is not clear whether this adaptive relaxation is
neurally-mediated, or relies on passive compliance of the gallbladder wall. Mourelle
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et al showed in anaesthetised guinea pigs and in isolated gallbladder muscle strips
that resting gallbladder pressure and contractions induced by CCK were enhanced by
L-NAME and abolished by sodium nitroprusside 252 and S-nitrosothiol 263. A
constitutive calcium dependent NOS was detected in gallbladder tissue homogenates
262
It remains unclear whether NANC innervation is present in the gallbladder.
Transmural field stimulation relaxed prairie dog ileal muscle but not gallbladder
although muscle from both organs relaxed in response to
S-nitroso-N-acetylpenicillamine (SNAP) with corresponding increases in cGMP
264concentrations . NANC innervation could not be found in human gallbladder
using EFS with adrenergic and cholinergic blockade 263. In contrast, a similar study
by McKirdy et al using EFS with a shorter pulse width, showed NANC inhibitory
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responses in 22 of 106 human gallbladder specimens . Furthermore, this NANC
relaxation was abolished by L-nitroarginine suggesting that NO could be the
neurotransmitter involved. This is supported by evidence from an in vivo study in
human that L-NMMA reduced the baseline gallbladder volume by about 15% and
significantly augmented gallbladder emptying induced by CCK infusion and fatty
meals 267. Therefore it appears that NO relaxes gallbladder contraction, but it is not
clear whether it is the mediator for NANC innervation in gallbladder.
2.3.2 Nitric oxide and the sphincter of Oddi
NANC neural relaxation is believed to be important in the mediation of the
6 1 • 968
relaxatory response of the SO to CCK in humans and the Australian opussum
C" m #
N "nitro-L-arginine methyl ester and oxyhaemoglobin both reduced the amplitude of
relaxations induced by EFS in the presence of adrenergic and cholinergic blockade in
isolated opussum SO precontracted with erythromycin; this effect could be partially
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reversed by L-arginine . Sodium nitroprusside mimicked the relaxations induced
by EFS. Furthermore histochemical staining of SO showed positive staining of
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NADPH-diaphorase in nerve cell bodies and nerve fibres in circular muscle
Systemic infusion of L-NAME increased SO's tonic pressure and amplitude of
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phasic contractions in guinea pigs and this effect was blocked by L-arginine 270.
CCK was known to contract the SO of guinea pigs and pre-treatment with L-NAME
significantly enhanced this contraction; sodium nitroprusside antagonised the
response to CCK "70. Constitutive Ca"+ dependent NOS activity was present in fresh
homogenates from guinea pigs and rabbit SO 270.
In humans, systemically administered gylceryltrinitrate has been demonstrated to
lower SO basal pressure and contraction amplitude; and gallstones have been
removed from intact papilla after glyceryltrinitrate induced relaxation 271'272.
Immunohistochemical labelling of human SO with anti-neuronal NOS showed
abundant positive staining in nerve fibres and bundles 273. Topical administration of
S-nitroso-N-acetylcysteine (SNAC) reduced SO tonic pressure and decreased the
frequency of phasic contractions *7j.
2.4 The enzymology ofNitric oxide synthase
NO biosynthesis from arginine is carried out by a class of enzymes known
collectively as the nitric oxide synthase (NOS). As might be expected on the basis of
its diverse and ubiquitous physiology in a wide variety of cells and tissues, there is a
wide variety of NOS isoforms 274. All of the NOS isoforms characterised have
common cofactors and prosthetic group requirements: NOS utilises O2 and
NADPH275 and requires FAD, FMN 276 and tetrahydrobiopterin 277 for activity. They
also have a strict requirement for L-arginine as D-arginine is a nonsubstrate. The
mechanism by which the different isoforms convert arginine to NO and citrulline is
likely to be the same as they all have common cofactors and prosthetic groups.
However, apart from differences in tissue or cellular origin, the isoforms do differ
with regard to their biophysical properties and in their mechanisms of regulation.
NOS can be divided into two distinct classes: an inducible class (iNOS) and a
constitutive class (cNOS). Within each class, subclasses exist. There are at least two
constitutive NOS with closely similar properties. One is the endothelial enzyme
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(eNOS) and the other the neural enzyme (nNOS), with localisation to brain and
peripheral NANC neurons.
Inducible NOS has been found in a wide variety of cells, for example, smooth
muscle, hepatocytes, microglial cells, endothelium, neutrophils and macrophages.
The iNOS in the macrophage differs from that in the endothelial cell, platelet and
brain in that it is not detectable in macrophage cell lines or freshly elicited
macrophages that have not been activated by lipopolysaccharide alone or in
combination with y-interferon 278 and it requires protein synthesis for its expression
277 ...
. iNOS is different from cNOS in that it is functionally calcium independent. All
reported cNOS isoforms are regulated by Ca2+ via the Ca2+-binding protein
calmodulin (CaM) 279. A Ca2+ -CaM complex forms upon influx of Ca2+ into the
cell, which then binds and activates cNOS. Thus, any event which results in the
2+influx of Ca~ into a cell containing cNOS can cause its activation and NO
production. For example, acetylcholine, bradykinin or shear stress can cause influx
of Ca2+ into endothelial cells and results in NO synthesis 274. In contrast, the
inducible enzyme from macrophages is not regulated by Ca2+ though it contains
tightly bound CaM which can be considered an enzyme subunit 2S0. Therefore in
iNOS, CaM is always bound regardless of Ca2+ levels and its activity is not regulated
by Ca2+.
cNOS synthesises small amounts of NO on demands in response to agonists and is
under stricter regulatory control than iNOS as the NO released is involved in
maintenance of vascular tone and neurotransmission 274. The agonists of cNOS are
substances released form nerves, such as acetylcholine, bradykinin and excitatory
amino acids, and those released from platelets e.g. thrombin, ADP and serotonin.
Pharmacological activators are calcium ionophores 161,281. In contrast to cNOS, iNOS
releases large amounts of NO continuously; the amount released per unit of time
from fully induced macrophages is a thousand times higher than that released from
NOS in endothelial cells. The molecular targets in the victim cells are copper and
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iron containing proteins, releasing free Cu2+ and Fe"+, and generating O2" apj
toxic hydroxyl radicals resulting in lethal oxidative injury in the victim cells l7'
Table 2.1 Similarities and differences between the two NOS.
Constitutive Inducible
NADPH dependent NADPH dependent
Dioxygenase Dioxygenase
Inhibited by L-arginine analogs Inhibited by L-arginine analogs
Ca2+/calmodulin dependent Ca" /calmodulin independent
Picomoles NO released Nanomoles NO released
Short lasting release Long lasting release
Unaffected by glucocorticoids Induction inhibited by glucocorticoids
Glucocorticoids inhibited the induction but not the activity in vitro of iNOS in
endothelium and macrophages after stimulation with lipopolysaccharides, either
alone or in combination with interferon 273. The induction by lipopolysaccharides of
the NOS in vascular tissues in vitro and the accompanying vascular relaxation, the
hyporesponsiveness to vasoconstrictors, and the increase in cGMP were inhibited by
incubation with dexamethasone 179. This suggests that immunologically induced
release ofNO may indeed explain at least some of the pathophysiologically features
of endotoxin shock. This action of glucocorticoids, which occurs at the low
concentrations achieved in plasma during the therapeutic use of these compounds,
correlates with their anti-inflammatory potency.
Considering the various mechanisms by which it is regulated and its requirement for
so many cofactors and/or prosthetic groups, inhibition of NOS can be envisioned to
occur in a variety of different ways. Inhibition of either iNOS or cNOS could occur
by utilising agents which compete for L-arginine, NADPH, flavin or tetrahydropterin
binding to the enzyme. Both cNOS and iNOS require NADPH-dependent FAD and
FMN. Diphenyleneiodonium and its analogs are known inhibitors of
NADPH-flavoproteins and were found to be potent inhibitors of iNOS from
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macrophages and cNOS from endothelial cells 274. Inhibition of tetrahydropterin
biosynthesis can result in a loss of iNOS and cNOS activity in macrophages and
endothelial cells 274. As cNOS can be activated by Ca2+ via the reversible binding of
CaM, CaM inhibitors calmidazolium was found to inhibit the endothelium cNOS
dependent relaxation of rat thoracic aorta but had little effect on restoring the
contractility of aorta with induced iNOS which was not dependent on CaM 282.
By far, analogs of arginine represent the largest and potentially most useful class of
NOS inhibitors. Many of the previously mentioned inhibitors are inappropriate as in
vivo inhibitors due to their non specific effects since many of these cofactors and
prosthetic groups, for eg. NADPH, flavin, tetrahydropterin or CaM are utilised for
other enzymatic reactions throughout the body.
A variety of arginine analogs have been found to be inhibitors ofNOS activity. One
of the most utilised and studied of these analogs is the methylated L-arginine
analogue N -monomethyl-L-arginine (L-NMMA). The inhibition ofNOS occurs by
combination of competitive inhibition and irreversible inactivation of enzymes 274.
Other L-arginine analogues that have been described as NOS inhibitors in vascular
tissues are NG-nitro-L-arginine (L-NNA), its methyl ester L-NAME, and
N-iminoethyl-L-ornithine (L-NIO) 179. L-NIO is approximately five times more
potent than the other analogues, suggesting that there may be differences in uptake,
distribution or metabolism of these compounds.
As mentioned in previous sections, NOS has been identified by
immunohistochemistry technique in a variety of tissues. Constitutive enzyme with a
molecular weight of-160 kDa has been purified from rat cerebellum 279. The gene
has been cloned and the deduced amino acid sequence showed that the molecule had
recognition sites for NADPH, FAD, FMN and CaM 283. Another cNOS has been
isolated from native bovine endothelial cells and found to be of molecular weight
-135 kDa 284. The inducible enzyme has also been purified to homogeneity from
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murine macrophages 285 ancj further studies on cloning and sequencing of this
enzyme showed 40% homology with the rat brain enzyme 286.
Antisera was raised in rabbits to rat brain enzyme and immunoreactivity was detected
1 87
in brain, posterior pituitary, adrenal medulla, eye and intestine . Two peptides
were selected from the published sequence of the rat brain enzyme and synthesised
for making the antibody 283. These were peptide 49, corresponding to amino acids
251-270 and is situated close to the amino-terminal of neuronal NOS, and the
carboxyl-terminal peptide 58, corresponding to amino acids 1409-1429. The
antibody so raised showed strong reaction with the ~ 160 kDa protein in human brain
extracts on Western blots 287. In the human gut, staining was seen in the myenteric
and submucous plexus, in both the neuronal cell bodies and fibres, and in nerve
fibres within smooth muscle of the gut. Staining was seen in many areas of the
human central nervous system, particularly cortex, hippocampus, hypothalamus,
cerebellum, brain stem and spinal cord. Immunostaining with this antibody was also
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seen in the endothelium of blood vessels from human lungs, liver and skin . The
antibody reacted with enzyme of molecular weights between 125 and 140 kDa in
these tissues. These could represent an endothelial form of the enzyme which is
known to have molecular weights of 135 kDa 284. Therefore, polyclonal antibodies
raised to rat neuronal NOS recognise the neuronal form of the enzyme as well as
other isoforms in the endothelium of human tissue. This finding indicates some
degree of homology between the isoforms.
NADPH-diaphorase activity has been shown to be a reliable marker of neuronal NOS
on the basis of its colocalisation with NOS-like immunoreactivity and NOS
messenger RNA 189'288"290. It has been shown that NOS activity is identical with
NADPH-diaphorase in central and peripheral neural tissue 189'291. ajso
NADPH-diaphorase and NOS were shown to coexist in enteric neurone 235>292>293.
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THE POST CHOLECYSTECTOMY SYNDROME
3.1 Introduction
Gallstones affects 10 to 20% of the UK population and the incidence increases with
advancing age. In 1993, cholecystectomy was performed at the rate of 1028.4 per
million population in Scotland 294, making it one of the most common surgical
procedures. However, not all cholecystectomy results in successful alleviation of
symptoms. The term "post-cholecystectomy syndrome" has been used to describe a
syndrome after cholecystectomy in which the pain is similar to that experienced by the
patients before surgery.
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Gallstones are usually "silent" " or infrequently become symptomatic
Several studies have demonstrated that most persons with minimally symptomatic or
"silent" gallstones remained free of symptoms and serious complications for
0QQ n 1
prolonged periods and therefore do not require specific therapy " . The
cumulative probability of developing biliary colic after 10 years was 15% in the
study by Gracie and Ransahoff 299 and 25.8% in the GREPCO Study 302. Ransahoff
and colleagues suggested that prophylactic cholecystectomy for asymptomatic
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gallstones was unnecessary J . In contrast, patients who had experienced biliary
type pain usually continued to have recurrent symptoms j01 or went on to develop
complications J°4. Wenckert and Robertson 304found that a third of patients
developed severe disabling biliary pain and a fifth acute cholecystitis or other serious
complications over an 11 years period. Patients who develop biliary colic or acute
cholecystitis should therefore be treated by cholecystectomy.
3.1.1 Historical data from open cholecystectomy.
Studies that have assessed symptomatic outcome after open cholecystectomy have
given varying results for the incidence of persistent pain after cholecystectomy.
Studies from the 1960's suggested that the incidence of postcholecystectomy
symptoms was between 18 to 43 percent ■5°:i~j07. in the 1980's, Ros and Gambon
TOR
evaluated 93 patients before and two years after cholecystectomy . Only 53
patients were completely symptom free at two years. The authors observed that
patients with a shorter duration of symptoms before cholecystectomy achieved a
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higher cure rate than those with a longer preoperative history . Through
retrospective case notes review and questionnaires sent to patients' general
practitioners, Konsten et al j09 reported an incidence of symptoms of 18% at a
median interval of 10 years after cholecystectomy. The authors also noted that
patients with typical symptoms of gallstone disease before surgery had significantly
fewer complaints during follow-up than those with atypical symptoms. Typical
biliary pain was defined by the Rome working group report310 as colicky pain in the
right upper quadrant of the abdomen. Gilliland and Traverso followed up over 600
patients over a mean follow up of 45 months and found that 88% of patients had
complete symptomatic relief after cholecystectomy 311. It was again noted that
patients without the pain of biliary colic were less likely (75%) to obtain symptom
relief from cholecystectomy. Dyspepsia was the most common residual symptom
after cholecystectomy in this subset, occurring in 32 percent.
The varying incidence of postcholecystectomy syndrome can be ascribed to the
varying methods of evaluation, symptoms being assessed and case mix of patients'
indications for surgery. Words such as "dyspepsia" and "flatulence" mean different
things to many patients. Flatulent dyspepsia has been defined as "epigastric
discomfort after meals, a feeling of fullness so that tight clothing is loosened,
eructation with temporary relief, and regurgitation of sour fluid to the mouth with
heartburn". Clearly, this is a rather loose definition as many of the features are also
found in patients with gastroesophageal reflux disease or peptic ulcer disease.
3.1.2 Incidence from laparoscopic cholecystectomy
There have been few studies on the symptomatic outcome following laparoscopic
cholecystectomy. In a 3-month follow-up of 52 patients, Peters et al reported that 77
in
percent of patients considered their symptoms to be cured . In a comparative study
of open and laparoscopic cholecystectomy, Vander Velpen et al reported that 95
percent of patients considered that they had obtained overall symptomatic
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improvement . Qureshi et al analysed perceptions of postoperative symptoms and
global satisfaction jI4. They noted that 25 percent of patients complained of more
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than two symptoms postoperatively but 84 percent considered the procedure to be a
complete success. Wilson and Macintyre evaluated symptomatic outcome of 115
patients a year after laparoscopic cholecystectomy and compared the outcome with
that in 200 patients who had undergone the open procedure. Over 90 percent of
patients in both groups considered the procedures to be successful3I5.
3.1.3 Causes of post-cholecystectomy pain
Upper abdominal pain is the major symptom of gallstone disease 293'298'j16-j18 but the
quality, duration, periodicity and frequency of pain most characteristics for
cholelithiasis remain uncertain jI7"j2j5 even in patients presenting with acute upper
abdominal pain j24. It is difficult to be certain in any one patient whether the
abdominal pain is due to gallstones or other upper abdominal pathologies as all may
produce similar symptoms. Incorrect preoperative symptom assessment may be an
important reason for poor outcome in cholecystectomised patients.
The majority of patients with the post-cholecystectomy syndrome have symptoms
originating from the oesophagus, stomach or duodenum. Gastroscopy and barium
meals may identify these diseases. Other patients have functional bowel disorders
such as irritable bowel syndrome or non-ulcer dyspepsia. Meticulous assessment is
therefore required before cholecystectomy.
Only relatively small number of patients with postcholecystectomy pain have biliary
tract diseases such as common bile duct stones, ampullary tumour or sphincter of
Oddi dysfunction j2\
3.2 SO dysfunction
SO dysfunction has been estimated to account for 1 to 10% of patients with
post-cholecystectomy pain 326. The possible aetiologies are discussed in 10.4.
3.2.1 Clinical characteristics
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SO dysfunction continues to be a poorly defined syndrome despite significant
progress in endoscopy and manometry. Many such patients have undergone
cholecystectomy without discernible abnormalities in the gallbladder. There is a
preponderance of middle aged women. Abdominal pain remains the most common
presenting symptom occurring a variable time after cholecystectomy. The pain is
similar to the one before surgery and is usually located at epigastrium or right upper
quadrant and may radiate to the back or shoulder blade. It is usually precipitated by
food and may be associated with nausea or vomiting. Jaundice and cholangitis are
rarely observed 325. Physical examination is usually unremarkable. There may be a
transient rise in liver function tests such as alkaline phosphatase, ALT or GGT during
attacks of pain. Some patients may present with acute recurrent pancreatitis.
3.2.2 Classification
SO dysfunction is classified as fixed structural stenosis or transient dyskinesia.
Stenosis is thought to be caused by the passage of gravel and surgical
instrumentation, with resulting oedema, fibrosis and a fixed narrowing of the SO that
may fail to respond to a variety of neural, physiologic or pharmacologic stimuli. SO
stenosis is defined manometrically as fixed, elevated basal sphincter pressure
(>40mmHg) that is unresponsive to CCK or amylnitrate. SO dyskinesia consists of
three motor abnormalities: (1) transient elevation of basal sphincter pressure
(>40mmHg) which relaxes to CCK or amylnitrate, (2) increased number of phasic
contractions (>7 per minute) and (3) increased percentage of phasic contractions that
propagate retrogradely (see table 5.4 ). Geenen and Hogan classified SO dysfunction
as type I to III (table 3.1 and 3.2) 327'j28 classification separates patients into
subgroups based on a number of clinical, laboratory and radiographic findings. This
classification has been criticised for being empirical and lacks discrimination for
patients subsets. It has only been validated for patients with previous
cholecystectomy. It is cumbersome and impractical to determine delayed drainage of
contrast from the biliary tree, which is one of the scoring criteria. The proponents
argue that it forms a useful common standard by which differrent studies can be
compared 329.
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Table 3.1 Sphincter of Oddi dysfunction: Biliary type.
Group 1 Recurrent biliary pain.
Twofold elevation in aspartate aminotransferase or alkaline phosphatase
Prolonged common bile duct drainage time (>45 minutes)
Dilated bile duct(>12mm)
Group 2 Biliary-type pain plus 1 or 2 of Group 1 criteria
Group 3 Biliary-type pain only
Table 3.2 Sphincter ofOddi dvsfunction: Pancreatic type
Group 1 Recurrent pancreatitis or recurrent pain with amylase or lipase elevation
Twofold elevation in aspartate aminotransferase or alkaline
phosphatase.
Dilatation of pancreatic duct (>5mm head,>4mm body)
Prolonged pancreatic duct drainage time (>9 minutes)
Group 2 One or two of group 1 criteria
Group 3 Pancreatic-type pain with normal enzymes and pancreatogram
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3.2.3 Investigations
Non-invasive diagnostic investigations of patients with suspected SO dysfunction
can be performed by the morphine-prostigmine test, quantitative hepatobiliary
scintigraphy (QHBS) and the fatty meal scintigraphy (FMS).
(1) Morphine-prostigmine test
Intramuscular injection of morphine and neostigmine is followed up to 5 hour by
determination of liver function tests. The test is considered positive if pain is
reproduced and liver enzymes increase to more than two times the upper normal
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limit. Several studies have shown that sensitivity and specificity are poor
(2) Fatty-meal sonography
Common bile duct (CBD) diameter is generally regarded to be slightly dilated after
cholecystectomy as it assumes a reservoir function and 7 mm is regarded as the upper
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limit of normal as measured ultrasonographically . CBD measurement is made
before and 45 minutes after ingestion of a fatty meal (Lipomul 1.5 mL/kg, Mead
Johnson Laboratories). CCK released after the meal stimulates increased hepatic
flow, contraction of the gallbladder (if present) and relaxation of the SO. Darweesh
et al defined a positive response as increase in the diameter of the CBD ofmore than
2mm j28. Using these criteria, a sensitivity of 74% and specificity of 100% for
partial CBD obstruction was obtained. Hepatocellular diseases do not affect the
FMS.
(3) Quantitative hepatobiliary scintigraphy
The test involves a large field-of-view gamma camera and administration of
technetium99"1 labelled radiopharmaceuticals that are actively taken up by
hepatocytes and excreted into the biliary tree. The most common
radiopharmaceuticals used are Tc99m-HIDA (dimethyl-iminodiacetic acid),
Tc99m-EHIDA (2,6 diethylphenylcarbamoylmethyl diacetic acid), Tc99m-disofenin
and Tc99m-mebrofenin. Darweesh et al reported reduced hepatic clearance (<63%) at
45 minutes as the most sensitive indicator for partial CBD obstruction with 67%
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sensitivity and 85% specificity 331 , , •ine test cannot be used in the presence of
hepatocellular diseases.
FMS and QHBS were initially thought to show great promise in screening for SO
dysfunction but they do not differentiate SO dysfunction from other causes of distal
common bile duct obstruction. When the FMS or QHBS are positive, ERCP with or
without manometry should be considered to differentiate SO dysfunction from other
causes of distal CBD obstruction such as benign stricture, choledocholithiasis or
tumour. FMS and QHBS have recently been reported to be poorly correlated with
33-)
manometry and the diagnostic accuracy decreases from Type I to Type III
(4) Endoscopic Retrograde Cholangiopancreatography
ERCP demonstrates morphologic abnormalities. It is an essential investigation
before manometry as endoscopic evaluation of the papilla and peripapillary area can
reveal abnormalities such as papillitis, choledochocele and tumour. ERCP
demonstrates choledocholithiasis and tumours of the biliary tract. In SO dysfunction,
the biliary tree can appear normal. However, the following radiographic
abnormalities may occur: (1) dilatation ofCBD to more than 12mm. This is the most
common radiographic abnormality noted among patients with SO dysfunction,
particularly in type I biliary dyskinesia. (2) delayed drainage of contrast from CBD
(>45 minutes), (3) dilatation of pancreatic duct (>6-7mm), (4) delayed drainage of
the pancreatic duct (>9 minutes) and (5) narrowing of the distal CBD with difficulty
of cannulation.
SO manometry remains the gold standard for the diagnosis of SO dysfunction.
However, the technique requires extensive experience of ERCP and manometry.
This is discussed further in section 5.3.
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CHAPTER FOUR
STATEMENT OF AIMS OF THESIS
4.1 Introduction and aims
Review of the literature reveals many unanswered questions relating to gallbladder and
SO function. The particular aims of the work described in this thesis are as follows.
1. To define the mechanisms of early gallbladder emptying. It has been known for
many decades that CCK is released from small intestinal mucosa in response to
83 86intraluminal fat and protein ' , and that CCK stimulates gallbladder contraction and
SO relaxation 4'5. This classical physiological pathway does not however explain the
observation that the gallbladder starts to empty immediately after ingestion of food,
many minutes before gastric emptying occurs and nutrients enter the duodenum. The
mechanism for the early phase of gallbladder emptying is unclear although it is
inhibited by atropine. Fisher et al 26,33j and Hansen et al 334 both demonstrated that
sham feeding caused gallbladder emptying in man and that this phase of gallbladder
emptying was inhibited by atropine and vagotomy. It therefore appears that a vagal
cholinergic reflex could be responsible for this early phase. Alternatively, it is possible
that gastric secretions produced by cephalic and oral stimulation, and gastric distension
may enter the duodenum and initiate gallbladder emptying via CCK released from
enterocytes. The first part of the thesis therefore investigated the mechanism of this
early phase of gallbladder emptying.
2. To determine whether NO influences gallbladder emptying and SO motility. The
enzyme NOS is responsible for the formation of NO from the amino acid L-arginine
and the activity of this enzyme is inhibited by an analogue of L-arginine,
L-A^-monomethyl-arginine (L-NMMA) 158. There is much evidence to show that the
L-arginine : NO pathway is an important component of NANC neurotransmission in
the lower oesophageal sphincter 205, colon and internal anal sphincter 246. The possible
role of NO upon gallbladder motility is unexplored. In a study of electrical field
stimulation, sparse inhibitory NANC activity was identified in isolated human
9 f\f\
gallbladder muscle strips . However, NO has not been systemically studied. The
effect ofNO upon gallbladder emptying and SO motility was examined.
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3. To investigate SO motility before and after LC. Upper abdominal pain after
cholecystectomy is a well recognised phenomenon. It is sometimes attributed to SO
dysfunction after exclusion of biliary stones and strictures. The syndrome is well
described by Geenen et al . The majority of patients with objective signs of
disturbed bile flow (elevated liver enzymes, dilated common bile duct and delayed
drainage of contrast during ERCP) also have abnormal manometry. However, in these
studies SO manometry was performed only in patients after cholecystectomy and it is
unknown whether biliary dyskinesia is a consequence of denervation incurred during
cholecystectomy. Denervation could disrupt CCK responsive descending inhibitory
nerves and thereby leave CCK mediated smooth muscle contraction unopposed. We
therefore investigated prospectively SO motility before and after laparoscopic
cholecystectomy (LC).
4. To determine the incidence of post-cholecystectomv syndrome. A small number of
patients continue to have a variety of gastrointestinal symptoms following LC. The
term "'post-cholecystectomy syndrome" has been used to describe this condition.
The reported incidence of post-cholecystectomy syndrome varies widely. Studies on
the symptomatic outcome after LC have reported successful relief of symptoms in
70% 312,314 to 95% of patients jl3'j15 but the characteristics of patients who continue
to experience pain after surgery are poorly defined.
LC has almost completely replaced open cholecystectomy but the incidence of
persistent pain after LC is poorly documented. We therefore prospectively assessed the
incidence of the LC syndrome 6 months after surgery using standard questionnaire.
4.2 Plan of investigation
Firstly, the sensitivity and reproducibility of ultrasonic measurement of gallbladder
volume were determined (see 4.2). The coefficient of variation of ultrasonic
measurement of gallbladder volume was calculated. As the study involved repeated
measurements of gallbladder emptying in the same individuals, reproducibility of
gallbladder emptying after standard meals was determined.
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As gallbladder smooth muscle contraction depends on the menstrual cycle, only male
volunteers were chosen for gallbladder emptying studies. The mechanism of the early
phase of gallbladder emptying was examined by subjecting volunteers to ingestion of
fatty food, modified sham feeding and gaseous gastric distension. Gallbladder
volumes, plasma immunoreactive CCK and gastrin concentrations were measured.
The role of nitric oxide in gallbladder smooth muscle contraction was examined in
vitro using isolated bovine and human gallbladder muscle strips. The strips were set up
in water baths; contraction and changes in muscle tension were measured using
isometric transducers. The muscle strips were contracted with CCK and the effect of
NO examined by adding NO donors (glyceryltrinitrate and sodium nitroprusside).
Human gallbladders were stained immunohistologically for NOS. This was followed
by an in vivo experiment involving a group of healthy male volunteers. Gallbladder
emptying after fatty meal was observed during intravenous infusion with normal saline,
NO donors and hydralazine as a hypotensive control agent.
SO motility was studied manometrically. Patients undergoing SO manometry for
investigation of abdominal pain were enrolled into the study for the effects of nitric
oxide on SO motility. After the recording of motility indices, glyceryltrinitrate was
applied topically on the ampulla and further recording was obtained for further two
minutes. Another group of patients awaiting LC for cholelithiasis volunteered for the
experiment examining the changes of SO motility caused by cholecystectomy. SO




5.1 Measurements of gallbladder emptying
In experimental models, gallbladder motility can be measured by directly cannulating
the intact gallbladder and measuring the intraluminal pressure. Isolated gallbladder
tissue can be obtained from either patients or experimental animals and contraction
assessed in organ baths with transducers. Alternatively gallbladder emptying can be
assessed in vivo either by serially measuring gallbladder volumes using
cholecystography or sonography, or by measuring the turnover rate of bile in the
gallbladder by scintigraphy or aspiration of bile through an indwelling catheter placed
in the duodenum 335'336.
5.1.1 Scintigraphy
Scintigraphy involves radioisotope scanning over the gallbladder after the
administration of a radiolabeled cholecystographic agent such as "mTc-HIDA 337'338.
Provided hepatic functions is normal, "mTc-HIDA is rapidly excreted in bile when
administered intravenously. Serial images are obtained as the isotope accumulates in
the gallbladder. After correction of natural decline in radioactivity over time, the decay
of radioactivity in minutes over gallbladder represents changes in gallbladder volumes.
It monitors the kinetics of gallbladder filling and emptying and measures changes in
gallbladder volumes through changes in radioactivity. It does not however measure
changes in absolute gallbladder volumes. Its usefulness is limited by the need for fairly
complex equipment and by radiation exposure. Therefore repeated measurements may
be hazardous during experimental conditions.
5.1.2 Aspiration method
The aspiration method involves aspiration of bile from the duodenum and the use of
• • • TOQ
nonabsorbable markers which facilitate calculation of bile acid and bilirubin output
The rate and duration of gallbladder emptying can be calculated but gallbladder
volumes or extent of emptying cannot be ascertained. It is an invasive method and
uncomfortable method which cannot be applied repeatedly.
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5.1.3 Ultrasound
With the use of newer high resolution sector real time ultrasound systems, sonography
has replaced cholecystography in the imaging of biliary systems in clinical practice for
many years. It identifies stones, sludge and wall thickening. It can be performed
rapidly and repeatedly without radiation or contrast administration. Absolute volumes
and extent of emptying can be measured. It is simple, safe and well tolerated technique
yielding rapidly acquired data.
(1) Methods
The measurement of gallbladder volume by a geometric method, called the sum of
cylinders method, was originally described in 1948 by de Silva using
cholecystography. The method assumes that the gallbladder is a pear shaped organ that
can be cut into a series of small cylinders of equal heights (h) that can be stacked one
above the other. A grid is placed on the optimal longitudinal gallbladder image so that
the lines spaced at 1 cm apart are oriented at 90° to the longitudinal gallbladder axis.
When the gallbladder is curved, as it often is, the longitudinal axis is displaced from the
central axis (figure 4.1). This causes the diameter measured from the longitudinal
projection to be smaller than the true diameter of the gallbladder (figure 5.1). Everson
et al modified de Silva's method slightly by applying the correction factor (E) to
account for the change in curvature of the gallbladder335.
The formula for gallbladder volume is :
n
V= 0.785hE2 (Z di2)
i=l
where h and d are the respective height and diameter of the ith cylinder and n
represents the total number of cylinders.
(2) Limitations.
It is assumed that the displacement of the longitudinal projection from the central axis
is uniform throughout the length of the gallbladder. This is not always true, especially
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ill long, narrow tapering segments of the gallbladder, where volume is small. The
volume in these areas would be over estimated slightly, but the effect on total volume is
minimal. The gallbladder also has segmentations and septa which influence the
calculation of volume by the geometric method.
The sum of cylinders method has been used effectively in investigative studies of
gallbladder volume in health and disease j4 j40. it gives a good approximation of
gallbladder volume but requires computational software in the calculation of volume
and this option is not generally available. Dodds et al subsequently compared
gallbladder volumes calculated by the simple ellipsoid method with the sum of
cylinders method and showed that the two methods give comparable values 34'. The
formula for the ellipsoid method is :
V=7t/6 (L x W x H )
where L is the length, W is the width, and H is the height.
The work in this thesis employed this ellipsoid method.
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Figure 5.1 A. Diagram showing relationship of "a", central axis of the gallbladder, "a7"
longitudinal axis from the sonogram, and "c" short axis from the sonogram. B. Sketch
of ultrasound longitudinal projection (—) superimposed upon actual size( ) of
gallbladder. The short axis projection is also shown with diameter "d" and "d1 . d1 is
the diameter which is measured from the sonographic longitudinal long axis.
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5.2 Reproducibility of gallbladder emptying rates and intra-observer coefficient
of variation of ultrasound scans.
Some studies described in this thesis involved repeated measurement of gallbladder
emptying rates in the same individuals. Therefore day to day variations in fasting
gallbladder volumes and emptying rates, and the intra-observer accuracy in
determining gall bladder volumes by ultrasound were determined.
5.2.1 Methods
10 healthy volunteers (5 male, 5 female; median age 36.5 years, range 23-52) were
studied on two separate mornings after overnight fast. Images of gallbladder volumes
were obtained by a portable real time ultrasound system (Sonoline SX, Siemens,
Germany). The transducer was placed in a sagittal plane in the right upper quadrant of
the supine volunteer and positioned until the greatest length (longitudinal axis) of the
gallbladder was obtained. The image was then frozen on the oscillocope screen, and
the dimension (length) was measured on the screen with electronic calipers. The
transducer was then rotated 90° to obtain the image of the transverse axis of the
gallbladder until the greatest width and height dimensions were obtained. All
measurements were made from the inner gallbladder wall. In some volunteers, the
gallbladder was located high under the right subcostal border and a deep, held
inspiration was necessary for visualisation. The part of the oscilloscope screen
showing the measurements was covered with a screen away from the ultrasonographer
and the reading was noted by an assistant.
None of the subjects had gallstones. Pre-menopausal female volunteers were examined
during the luteal phase of their menstrual cycle. Smokers were requested to refrain
from smoking for at least six hours prior to scanning. None of the volunteers was
taking motility drugs. Each subject was requested to undergo the study on two separate
mornings.
The intraobserver i.e. intra-study, coefficient of variation was estimated by making five
measurements of fasting gall bladder volumes over a period of 10 minutes. It was
75
assumed that fasting gallbladders remained static over the 10 minute period.
Intra-observer coefficient of variations of gallbladder volume were then calculated ( SD
(standard deviation) over the means of the fasting volumes multiplied by 100) for each
individual subject. Inter-study (between day 1 and day 2) and inter-subject (for day 1
and 2) were determined from the fasting gallbladder volumes.
To determine day to day variation in gallbladder emptying, volunteers were requested
to ingest a standard fatty meal comprising a two egg omelette. Gallbladder volumes
were measured at 5 minute intervals for the first thirty minutes, at 10 minute intervals
for the second thirty minutes and at 15 minute intervals for the final thirty minutes.
Duplicate measurements were made at each time interval and the average volumes
calculated. Gallbladder volumes were expressed in millilitre and as percentage of
fasting volume at interval after ingestion of fatty meal. Fasting volumes, residual
volumes and percentage of fasting gallbladder volumes at each time interval were
noted.
To test for reproducibility of the rate of gallbladder emptying on two different days
under similar experimental condition, interstudy coefficient of variations at each time
intervals of the mean percentage of fasting gallbladder volumes were determined.
Written informed consent was obtained from each volunteer and the studies were
approved by the Lothian Ethical Subcommittee for Medicine and Oncology.
5.2.2. Results
Intra-study coefficient ofvariation
The means + SD of fasting volumes and intra-observer/intra-study coefficient of
variations for each subject are shown in table 5.1. Intra-observer coefficient of
variation in ultrasound measurement of gallbladder volume was below 12. The mean
intra-observer/intra-study coefficient of variation was found to be 7.7 (Range 3.6-11.3).
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Inter-subject coefficient ofvariation
The variation in fasting gallbladder volumes between subjects was wide, ranging from
4 to 30ml . Mean+SD of fasting gallbladder volumes for the group on day 1 and 2
were 19.1+6.5 and 21.7+8.6 ml respectively (table 5.1). The inter-subject coefficient of
variations for the two days were therefore (6.5/19.1 x 100= 34) and (8.6/21.7 x 100=
39.6). This wide variation in gallbladder volumes is well known and has been found
i 1 • 41 342
by other investigators ' .
Inter-study coefficient ofvariation
As shown in table 5.2, the mean of the difference (Day 1- Day 2) in fasting gallbladder
volumes on two separate days were 3.2+3.4. The mean of fasting gallbladder volumes
from the two days was (19.1+21.7)/2= 20.4 ml. The inter-study coefficient of
variation could be calculated from the SD of the difference divided by the mean of
fasting gallbladder volumes. This inter-study coefficient of variation was found to be
(3.4/20.4x100)= 16.7.
The mean fasting and residual gallbladder volumes for the whole group, and fasting
gallbladder volumes for the male and female volunteers are shown in table 5.3. The
mean fasting volumes were 19.1+6.5 ml and 21.7+8.6 ml on the first and second day
respectively. Male volunteers had significantly larger fasting gallbladder volumes than
female. The mean fasting volumes were 15.7+5.7 and 27.6+3.9 ml for the female and
male volunteers respectively (unpaired t test, p<0.05).
Reproducibility ofthe rate ofgallbladder emptying
Profiles of gallbladder emptying after standard fatty meals for the two days are shown
in figure 5.3. The difference between day 1 and day 2 in the percentage of fasting
gallbladder volumes at each time interval for each individual, and the means and
standard deviations of the difference, is shown in table 5.4. The means ofpercentage of
fasting gallbladder volumes at each time interval for the whole group is shown in table
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5.5. The coefficient of variations for gallbladder emptying at similar time interval on
two different days was then calculated by dividing the standard deviations of the
difference in the percentage of fasting gallbladder volumes by the means for the whole
group. As shown in table 5.5, the coefficient of variations ranges from 4.9-15.4. Apart
from three time intervals at 40th, 50th and 60th minute, the values are otherwise below
10. This result confirms the visual impression of figure 5.3 showing that the rate of
gallbladder emptying is reproducible under similar experimental condition.
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Table 5.1 Mean fasting gallbladder volumes (five repeated measurements per minute
and intra-observer coefficient of variation of ultrasound scan measurements ).
Subject Sex Mean fasting Mean fasting Coefficient of Coefficient of
volume+SD ml volume+SD ml variation variation
(day 1) (day 2) (day 1) (day 2)
1 female 7.1+0.4 4.6+0.5 5.6 10.8
2 female 13.1±1 14.5±1.1 7.6 7.6
o
J) female 13.4+1.5 13.2+0.7 11.2 5.3
4 female 21.6+2.2 24.8±1.5 10.0 6.1
5 female 19.7+2 21 -3±1.4 10.2 6.5
6 male 18.4+1.2 30.5+2.4 6.5 7.9
7 male 19+1.9 22.1±2 10 9.5
8 male 24.8±0.9 25.1+1.2 3.6 4.8
9 male 26.2+1.7 29.8±2.8 6.5 11.3
10 male 27.8+1.9 30.7+2.2 6.8 7.2
Mean fasting
volumes for the
group+SD ml 19.1±6.5 21.7+8.6
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Table 5.2. Means of fasting gallbladder volumes and the difference between day 1 and
day 2.
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Table 5.3 Mean fasting and residual gallbladder volumes for the whole group.
Mean+SD
Day 1 Fasting GB Volume (ml) 19.1±6.5
Day 2 Fasting GB Volume (ml) 21.7+8.6
Day 1 Residual GB Volume (ml) 4.5+3.7
Day 2 Residual GB Volume (ml) 3.1±2.2
Mean fasting volumes for female subjects (ml) 15.7+5.7
Mean fasting volumes for male subjects (ml) 27.6+3.9
oH 1 1 1 1 1 1 1 1 1 1











Figure 5.2 Gallbladder emptying rates on two different davs after ingestion of fatty
meal in ten subjects.
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Table 5.4, (Dav 1 - Dav 2) in the percentage of fasting gallbladder volumes at
different time points for individual subject and the means for the group.
Time/ (Day 1-Day 2) of the percentage of fasting gallbladder Means+SB
min volumes for individual subject
1 2 3 4 5 6 7 8 9 10
0 0 0 0 0 0 0 0 0 0 0 0
5 2 2.3 12.4 4.5 20 2 10 i I 14.4 7.2 8.7+6.4
10 11 19.5 18.5 9.6 9 6 18.4 8 13.2 11.3 12.6+5.1
15 6 15.7 13.1 11.7 5 1 10.8 3 3.8 7.2 7.8±5.1
20 5 6 5.8 17.8 13.1 4 11.9 11 12.1 8.9 9.6+4.6
25 19 5.8 11.9 10.9 3.9 3 8.8 8 8.1 8.3 8.8+4.8
30 1 3.6 3.6 12.1 7.7 4 4.3 5.0 10.1 9.8 5.6+3.5
40 8 12.5 3.2 15 17.4 1 3.0 2.0 1.5 6.9 7.1+5.4
50 8 2.7 3.4 10.7 3.3 1 0.1 2 5.4 1.7 3.6+3.7
60 52 1.3 4.1 2.7 1.9 4.3 5.4 1 8.8 4.8 3.5±2.4
75 62 0.2 0.1 1.6 2.0 0 1.8 1.1 1.4 2.7 1.1±0..8
90 73 0 0.8 0.9 3.9 1 1.2 0.3 0.3 3.4 1.3±1.3
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Table 5.5 Means of fasting gallbladder volumes on day 1 and 2. standard deviations
of the difference in percentage of fasting gallbladder volumes and the coefficient of
variation at each time intervals.
Time/min Means of percentage of fasting SD * Coefficient of
gallbladder volumes variations
Day 1 Day2 Means of day
1 and 2
0 100 100 100 0 0
5 91.2 84.4 87.8 6.4 7.3
10 79.9 81.7 80.8 5.1 6.3
15 67.1 73.7 70.4 5.1 7.2
20 63.7 63.9 63.8 4.6 7.2
25 51.9 51.9 51.9 4.8 9.2
30 44.8 45.8 45.3 3.5 7.7
40 32.9 33.3 33.1 5.4 13.3
50 24.1 23.9 24.0 3.7 15.4
60 18.7 18.6 18.7 2.4 12.8
75 16.3 16.3 16.3 0.8 4.9
90 15.6 16.1 15.8 1.3 8.2
* SD is the standard deviation of the (Day 1 - Day 2 ) of the percentage of fasting
gallbladder volumes at each time point for the group (see last column on table 5.4).
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5.3 SO manometry
SO manometry is the gold standard test for SO dysfunction. However, it is invasive
and the technique requires extensive endoscopic experience. The manometry
equipment is not generally available in most hospitals. Recording and interpretation
of manometric tracing requires computational software and a highly experienced
observer.
5.3.1 Water perfusion technique
(1) Methods
After overnight fast, patients were sedated with 5-10 mg intravenous midazolam.
This agent has been reported to have no effect on SO motility 343. Opiate related
drugs and glucagon were avoided as they interfere with SO motility. Patients were
given ciprofloxacin 500 mg two hours prior to SO manometry. The Olympus
JF1T10 side viewing endoscope was introduced into the stomach and advanced into
the duodenum with the patient in the left lateral position. Patients were then turned
onto the prone position prior to cannulation of the ampulla.
A triple-lumen polyethylene manometric catheter with an external diameter of 1.7
mm, luminal diameter of 0.5 mm and a length of 200 cm was used. It had three
lateral openings, 0.5 mm in diameter, located at 2 mm intervals. The most distal end
of the catheter was marked by eight black rings 2 mm apart to permit endoscopic
observations of the depth of catheter insertion into the ampulla.
For pressure recording, each catheter lumen was perfused continuously with
degassed sterile water by a low-compliance pneumohydraulic capillary infusion
pump at a flow rate of 0.25 ml/min (Arndorfer Medical Specialities) This was
connected via a transducer to a computerised polygraph (Albyn Medical Ver.6.0,
England). Transducers were calibrated before each study to produce a pressure rise
in excess of 250 mmHg/sec when occluded.
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After recording duodenal pressure, taken as the zero reference, the catheter was
deeply cannulated into the CBD. Pressure was recorded and the catheter was then
withdrawn across the SO in 2 mm increments using the black marks on the catheter
as a guide. The sphincter was identified as the zone of high resting pressure between
the duct, either pancreatic or choledochal, and the duodenal pressure with phasic
waves superimposed. Recording was obtained for at least 60 seconds at each station.
Ideally, the three tips should be recording phasic wave contractions simultaneously.
As soon as this occurred, the catheter was kept stationary at this position.
After at least two such pull-throughs, the catheter was repositioned so that all three
channels recorded phasic SO contractions. CCK (Cholecystokinin, Ferring
Pharmaceuticals, Malmo, Sweden) was injected intravenously at 1 IDU/kg
bodyweight over 60 seconds. After 30 seconds period to allow for equilibration of
drug concentration, recordings were continued for 2-3 minutes. The total duration of
recording lasted approximately 10 min. Selective bile duct cannulation was
facilitated by the careful positioning of, and direction of, the catheter relative to the
papilla. Other investigators perform radiological imaging to confirm catheter
position in either the CBD or pancreatic duct. This needs a radiopaque catheter to
determine whether the catheter advances towards the liver hilum in the CBD or
leftward in the pancreatic duct j44. Otherwise injection of contrast is needed.
Distension of the biliary tree is known to alter SO motility 69'345. Guelrud et al
verified catheter position by aspirating through the distal port before recording;
aspiration of bile is believed to indicate the position in the CBD whereas aspiration
of clear colourless fluid indicates the pancreatic duct 346.
In our studies verification was not performed because a facility for radiological
screening was unavailable. Furthermore SO motility were found to be similar for
CBD and pancreatic intubation 346'347.
Ductal pressure was known to show biphasic variations with respiration, rising on
inspiration and falling on expiration 344. Pressure varies in relation to posture.
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Duodenal, CBD and pancreatic duct pressures were found to be significantly higher
in the prone than in the left lateral position, probably because of the influence of
intra-abdominal pressure 344. The patient's position was therefore standardised in the
prone position during manometric recordings. Intra-gastric air distension has not
"3 JO
been observed to affect SO basal pressure
(2) Analysis ofmanometric recordings.
Four parameters were determined :(1) Duodenal pressure. This was determined from
the catheter prior to cannulation. The average duodenal pressure was 8+2 mmHg.
(2) Ductal pressure (CBD and pancreatic duct). These were usually 5 to 15 mmHg
above duodenal pressure (3) Basal SO pressure. Basal SO pressure was calculated by
subtracting the duodenal pressure from the baseline SO pressure between phasic
contractions in each of the channels. The SO tonic pressure was 5-8 mmHg above
CBD (or 15 to 30 mmHg above duodenal pressure). (4) Amplitude, frequency,
duration and direction of the phasic contractions of the sphincter. The amplitude was
measured from the beginning of the slope of pressure increase from the basal
pressure to the peak of the phasic contraction wave. Average phasic contractile
frequency was calculated as the number of phasic contractions divided by the
duration of the recording period during which contractions were identified. The
duration of phasic contractions in seconds was measured from the onset of the major
upstroke to the end of the wave. All measurements were expressed relative to
intraduodenal pressure which was defined as zero. Ductal pressure was calculated by
subtracting the duodenal pressure value from the pressure recorded in each of the
orifices. The amplitude of SO pressure was calculated as the average of maximal
contractile amplitude minus basal pressure in each of the three channels.
A motility index ( MI= Amplitude x Frequency ) was calculated as the product of the
SO mean phasic amplitude and frequency during the period of the recording j49.
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Figure 5.3 Manometric tracing of SO motility at paper speed of 4 cm/mirt (the top
three tracings represent proximal i.e. most cranial, middle and distal sphincter
pressure: the bottom tracing shows the duodenal pressure).
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Figure 5.3 is an example of a typical manometric tracing. Several manometric
characteristics have been identified as criteria for SO dysfunction (table 5.3). These
findings have been independently validated by different investigators 65'66>346'350-355_
Table 5.4 Criteria for abnormal manometry
Basal pressure >40 mmHg
Peak pressure >240mmHg
Paradoxical response to CCK
Frequency of phasic wave contractions>7
Retrograde contractions >50%
Elevated SO basal pressure is the most common abnormality. Endoscopic
sphincterotomy has been known to decrease the pressure with successful alleviation
of symptoms ' . In normal subjects, intravenously administered CCK decreases
SO pressure and abolishes phasic waves. In some patients with SO dysfunction,
CCK causes a paradoxical increase in basal pressure 354>35:). An increase in phasic
wave contraction greater than 7 per minute is considered to be abnormal. This is a
rarely observed finding in patients with SO dysfunction and is described as
Kz:
tachyoddia . Phasic wave contractions are propagated antegradely in normal
subjects. Retrograde phasic wave has been described but is rarely seen in patients
with SO dysfunction j5j.
Intrinsic variability of SO motor function has been evaluated by comparing two
perendoscopic SO manometric recordings performed in the same session or in
different sessions several days apart ' . No significant difference in the
manometric variables was found between the intra-session and inter-session
measurements. Intra-session measurements showed a high correlation for SO basal
pressure, SO length, the amplitude and frequency of phasic activity. Inter-session
measurements showed a high correlation for SO basal pressure and SO length and a
low correlation for amplitude, duration and frequency of phasic activity. It therefore
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appears that biologic time related variation of SO motor function affects phasic
contraction though resting basal SO pressure is unaffected. This is perhaps expected
as phasic contractions is affected by interdigestive motor cycles. Interestingly, one
study on healthy volunteers shows excellent reproducibility j46. Perhaps the inter-
session variability in the phasic contractions were noted in studies of patients with
suspected SO dysfunction and is due to the episodic nature of the disorder.
(3) Factors influencing interpretation ofmanometric findings
Several artifacts may be present. Intra-abdominal pressure variations due to retching,
coughing, deep breathing may be transmitted to the recording sensor. Variation in
the spatial relationship between the catheter and the papilla occurs during respiratory
effort, retching and body movement. Displacement of the catheter may also occur
during manometry. It is important for the manometrist to mark on the recording all
these events that interfere with interpretation of tracing. Another manometric
catheter probe is taped on the external surface of the endoscope which helps to
determine occurrence of duodenal contractions and retching (see bottom tracing on
figure 5.3). Contractile activity which occurs simultaneously with duodenal
contraction is ignored as it is felt to be secondary to duodenal contraction. An
artificial elevation of the pressure may be noted if the catheter tip is impacted against
the ductal wall. Defects in the perfusion system such as air bubbles, leakage or
occlusion of the catheter may reduce the sensitivity of the system.
The choledochal and pancreatic sphincters are distinct physiological entities,
corresponding to the anatomical structures described by Boyden. Evidence
supporting the pancreatic duct as a distinct physiological entity came from
manometric studies after endoscopic sphincterotomy " . The choledochal
sphincter was abolished following sphincterotomy while the pancreatic sphincter
continued to demonstrate normal motility. However, there was minimal increase in
the basal pressure and decrease in the amplitude of the pancreatic sphincter compared
with the choledochal readings j46'347. a proportion of patients (42%) with partial
CBD obstruction were found to have higher basal sphincter pressures in the
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choledochal sphincter alone or both of the sphincters. Similarly, 29% of patients
with acute recurrent pancreatitis had elevated pancreatic sphincter pressure alone or
in combination with choledochal sphincter. It therefore seems that the two sphincters
are functionally independent but yet related in their motor function as there do not
seem to be significant differences in the values of their motor activity.
(4) Complications
SO manometry is associated with cholangitis and pancreatitis. The overall incidence
of pancreatitis was estimated at 5% 361. The rate was higher in patients with
pre-existing pancreatitis. Twenty eight percent of patients with chronic pancreatitis
developed an exacerbation of their pancreatitis.
The aetiology of post-sphincter of Oddi manometry pancreatitis is unknown but
probably multifactorial. Mechanical trauma from cannulation, hypotonic injury from
sterile water, and hydrostatic injury from overfilling of pancreatic duct have all been
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implicated . Repeated attempts at cannulation can result in oedema and
subsequent occlusion of the papilla. During ERCP, the pancreatic ductal system
typically accepts 1 to 3 ml of contrast before acinarisation occurs. Therefore a
triple-lumen catheter that delivers 0.75 ml of perfusate per minute causes overfilling
and acinarisation after 1 to 2 minute. Bacterial cholangitis and pancreatitis should be
a rare occurrence with high grade disinfection and pre-procedure administration of
antibiotics.
Pancreatitis is very uncommon if only the choledochal sphincter is studied. When
manometry is performed in the pancreatic duct, repeated cannulation and prolonged
stationing of the catheter in the duct should be avoided to prevent pancreatitis. A
specially designed catheter that allows continuous aspiration of fluid from one of the
three lumen can maintain the pancreatic duct pressure at a low level. This catheter
has been shown to reduce the incidence of pancreatitis (23.5% versus 3%) although
this has only been reported from one centre 362.
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5.3.2 Microtransducer technique
A catheter with a miniaturised intraluminal transducer, 4 Fr in diameter, located at
the distal tip has been used by Japanese investigators to measure intraductal pressure
344. This system, which avoids the infusion of fluid, allows intrabiliary pressure to be
recorded for prolonged period of time and theoretically, avoids the risk of
pancreatitis due to over distension of pancreatic duct. No study has compared this
technique with the perfusion systems. The transducers are costly and subject to
baseline drift. They are not suitable for measuring SO pressure due to the difficulty
of keeping the sensor within the sphincter. The position of the catheter in the SO
could be maintained with the use of a guide wire that is passed into the centre of the
catheter. However, fluoroscopy is needed to check the position of the radiopaque
• i • • ■« T48
sensors in relation to the guide wire and duodenal wall . This technique looks
promising and offers the prospect of prolonged telemetric recording provided a
technique can be developed to station the transducer in the SO.
5.4 Isometric tension measurements of muscle strip in tissue baths
In vitro water bath experiments with isolated tissues allow direct examination of muscle
contractility with different reagents. The main stumbling block with experiments of this
nature was retrieval of viable human tissue from LC. Bovine gallbladders were therefore
studied.
5.4.1 Tissue preparation
Bovine gallbladders obtained from a local abattoir were used for the experiments. Tissue
was obtained half an hour to an hour after death of animals. Whole gallbladders were
removed and transported in flasks containing cooled (4°C), pre-oxygenated Kreb's
solution at pH 7.4. The Kreb's solution consisted of (mM): NaCl 118, NaHCCb 25, D-
dextrose 11, KC1 4.7, CaCh 2.5, MgSCh 1.2 and KH2PO4 1.2. The flasks were kept cool
in an ice box. Pieces of gallbladder (about 10 cm long and 10 cm wide) were placed in
a Petrie dish under cooled oxygenated Kreb's solution and four muscle strips (10 mm
long and 2-3 mm wide) were obtained from each gallbladder. The orientation of
muscle strips is not important as muscle fibres are loosely arranged in longitudinal,
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circular and oblique bundles Experiments were started within one hour after
removal. We have found bovine gallbladders to remain viable up to four hours after
removal. Strings were tied into knots at both ends and each strip was mounted for
isometric tension recording in four 10ml organ baths containing Kreb's solution at 37
°C, continuously bubbled with (XCCb ( 95%:5% ).
Muscle strips were equilibrated at basal tension lg for at least 1 hour before experiments.
Kreb's solution in the water baths was changed every 15 minutes. Four water baths could
be set up simultaneously.
5.4.2 Equipment
One end of the muscle strips was connected to an isometric transducer and chart recorder.
Changes in tension were monitored by isometric force transducers connected to a
MacLab Analog Digital Instruments and a personal computer with MacLab Chart
V3.2. (see figure 5.4). The polygraphs on the video screen show contractility of the
muscle strips in the four water baths simultaneously. For each graph, an area over
time could be "selected" and the computational software could then calculate the
mean tension which is the average of basal tension and peak of phasic contraction
over the specified time period. One minute was chosen as the standard time period
(see figure 5.5 for example of the polygraph).
5.4.3 Preparation of chemicals
1. Preparation ofL-NMMA
Raw materials :
1. L-A^-monomethyl-arginine (L-NMMA, Calbiochem-Novabiochem, UK).
Molecular weight is 248.
2. 0.9% sodium chloride injection B.P. (Baxter Healthcare Ltd, Thetford, Norfrolk,
UK)
Preparation :
1. L-NMMA was dissolved with normal saline to a dilution of lmg/ml (4xl0*3 M).
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2. Stock solutions of 2 and 4x10~3 M were then stored in plastic or glass containers at
-20°C and used within a week of preparation.
2. Preparation of cholecystokinin
Raw material:
1. Cholecystokinin (CCK) (Ferring Pharmaceuticals, Malmo, Sweden )
This preparation of CCK contains equimolar amounts of CCK33 (molecular weight
3663) and CCK39 (molecular weight 4541). The average molecular weight of the
preparation is thus 4102. lmg of the preparation contains approximately 1000 IDU.
Therefore 1 IDU is 0.00lmg in weight.
Preparation :
1. Three different stock solutions of cholecystokinin was prepared as follows:
2. An ampoule of CCK containing 70 IDU was dissolved into 70ml ofKreb's solution.
3. From the molecular weight of CCK, therefore 1 IDU/ml was equivalent to
(0.001/4102=2.4x10"7)M.
4. Three different stock concentrations of 10"7, 10~8, 10~9 were made.
5. These stock solutions were placed into glass or plastic containers and stored deep
frozen (-20°C) for no more than one week.
5. The solutions were thawed in a refrigerator before use.
3. Preparation of glyceryltrinitrate
Raw material:
1. Glyceryltrinitrate (Nitrocine, Schwarz Pharma, UK). Molecular weight is 227.1
Preparation:
Glyceryltrinitrate was purchased in lOmg ampoules each at concentration of lmg/ml.
Glyceryltrinitrate was used at this concentration that was approximately 5xl0"3M.
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4. Preparation of sodium nitroprusside
Materials :
1. Sodium nitroprusside (Sigma, St Louis, USA). Molecular weight was 298.
Preparation:
Stock solution of ICT'M is made by dissolving 21mg of sodium nitroprusside in 1ml of
solution. The stock solution is prepared fresh before use and the glass container is
immediately covered with aluminium foil.
5. Preparation of potassium chloride (KC1)
200|_il of 1M stock solutions, when diluted in 10ml of Kreb's solution, would achieve
KC1 concentration of 20mM
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Figure 5.5 Typical polygraph showing contractility of muscle strips. The v-axis
represents tension in gram: each graph shows muscle strip contractility in each water
hath. The pattern of muscle contractility is different although all the strips were taken
from adjacent areas of gallbladder.
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5.4.4 Dose response curve for KC1
(1) Method
The dose response to KC1 was examined at cumulative bath concentrations of 20
mM-100 mM. After one hour of equilibration, muscle strips were stimulated to contract
with KC1. At each concentration of KC1, five minutes was allowed for muscle strips to
achieve maximum contraction before the tension was noted. Four strips from each of six
gallbladders were examined (n=24).
(2) Results
Some muscle strips showed spontaneous basal contraction with superimposed phasic
contractions. KC1 achieved immediate contraction with increase of tone and stimulation
ofphasic activity. The dose response curve ofKC1 is shown in figure 5.6. The maximum
increase in tension was 3.5g. From the curve, the effective concentration at 80% (ECgo)
is calculated to be 50 mM.
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KC1 conc/mM
Figure 5.6 Dose response curve for potassium chloride.
5.4.5 Maximal basal tension in response to ECso KCI concentration
The aim of this experiment was to determine the basal tension that achieved maximum
contraction in response to 50 mM KCI.
(1) Method
Four muscle strips were obtained from eight gallbladders. Muscle strips were each
equilibrated at a basal tension ranging from 1 to 4g for an hour. They were then
stimulated to contract with 50 mM KCI. The maximum tension reached after five
minutes was recorded. The mean increase in tension at each basal tension was calculated.
(2) Results
Some of the muscle strips had spontaneous tonic and phasic activity. Consequently, the
actual basal tension after the equilibration period was sometimes higher than the
designated basal tension for those muscle strips adjusted at a basal tension of 1 g. The
tension increased from 1 to 1.6+0.3 g. There was progressive increase in contractility as
the basal tension was increased from 1 g to 3 g; the degree of contraction became
suboptimal as the basal tension was increased to 4 g (see figure 5.7). Basal tension of 2
g and 3 g produced significantly higher degree of contraction (ANOVA). However, the
change in tension between basal tension of 2 g and 3 g was not significantly different
(t-test); therefore 2 g basal tension was chosen as the basal tension for subsequent
experiments.
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Initial designated Basal tension after Tension after KCI+ Change of
basal tension (g) equilibration+SE (g) SE (g) tension+SE (g)
1 1.6+0.3 3.2+0.4 2.2+0.4
2 2.1+0.2 5.1+0.4 3.3+0.4
3 p 1+© 6.6±0.5 3.5±0.5
4 4.1+0.1 5.3+0.3 1.1+0.4
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0 1 2 3 4 5
Basal tension/g
Figure 5.7 Increase of tension after stimulation with 50 mM KC1 at varying basal tension.
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5.4.6 Dose response curve for CCK
(1) Method
The final part of this initial experiment was to determine the 50% effective concentration
(EC50) for CCK. Muscle strips were equilibrated for an hour at basal tension of 2g. Five
gallbladders were examined at cumulative bath concentrations of CCK between 10'" to
l.OxlO"9 M; five further gallbladders were subsequently examined at cumulative
9 8concentration between 5.0x10" M to 1.8x10" M. Five minutes intervals were allowed at
each concentration before addition of further stock CCK solutions.
(2) Results
o
Maximum contraction was achieved at CCK concentration of 1.2x10" M. EC50 for CCK






l.OxlO13 l.OxlO"12 1.0xl0u l.OxlO10 l.OxlO09 1.0xl0os 1.0x10"
CCK conc. (mM)
Figure 5.8 Cumulative dose response for CCK.
5.5 Radioimmunoassay
Blood samples were obtained from an intravenous catheter and were kept on ice;
plasma was separated within 30 minutes and stored at -70°C for subsequent assay of
cholecystokinin (CCK) and gastrin. Plasma CCK and gastrin were measured by Drs.
Joy Ardill and Lee Armstrong at Department ofMedicine, Queen's University, Belfast.
5.5.1 Cholecystokinin
Plasma CCK concentrations were measured using a highly sensitive and specific
radioimmunoassay. The antiserum R7(3) used, binds to all carboxy-terminal CCK
peptides containing the sulphated tyrosine. Relative cross reactivity with CCK8 is
1.0, CCK33 is 0.72, CCK39 is 0.7. Cross reaction with sulphated gastrins is less
than 1% and no cross reaction is observed with other gastrointestinal peptides.
Synthetic CCK8 labelled l25I using Bolton and Hunter Reagent (Amersham,
England) was used as tracer and synthetic sulphated CCK8 (Bachem, England) was
used as standard. Separation of antibody-bound from free peptide was achieved
using dextran coated microfine charcoal. The detection limit of the assay was 1 ng/L
(1 pmol/L) and intraassay and interassay variation was 8% and 11% respectively at
5 ng/L.
5.5.2 Gastrin
Plasma gastrin was measured by radioimmunoassay as previously described by
Ardill j6j>. All gastrin measurements were performed using a C-terminal reactive
antiserum (R98) which measures only amidated gastrins. R98 detects G17 and G34
in equimolar concentration and measures both sulphated and unsulphated variants.
Cross reactivity with CCK is <0.001%. The assay as used in this study had a
detection limit of 2ng/L (1pmol/L) and intra and interassay variation was 4.6 and




Gastric emptying of a radio-labelled omelette was measured. Omelettes were radiolabeled
V/rith 4mBq of Tc "m sulphur colloid as described by Millar et alj64. Previous validation
method had shown that less than 1% of the radiolabel became separated from the test meal
during incubation with gastric acid 364 Subjects were positioned in front of a gamma
camera counter and anterior and posterior scans were obtained after the omelette had been
swallowed. An area of interest over the stomach was identified and pairs of frames were
obtained at 2 minute intervals. The median of anterior and posterior radioactivity were
calculated. Gastric emptying was calculated as described by Millar et al using a computer
which plotted best fit for the data.
5.7 Immunohistochemistrv of NOS
Tissue specimens were prepared for immunohistochemistry by standard methods.
Paraffin embedded sections were washed with xylene and alcohol. Sections were
rehydrated in distilled water for five minutes and endogenous peroxidase activity
were removed with 2% H2O2 in 60% methanol for thirty minutes. Slides were
covered with normal sheep serum in phosphate buffered saline (PBS) and incubated
overnight with neuronal specific NOS antiserum. Antiserum to neuronal specific
NOS was purchased from Affiniti Research Products Limited, Exeter, UK. The
synthetically manufactured peptides corresponded to amino acid residues 1414-1429
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of the rat neuronal NOS-1 protein modified to facilitate specific N-terminal
conjugation to a carrier protein. The primary antibody was applied at dilution
between 1/200 to 1/1000 in Tris buffered saline (TBS) containing 1% bovine serum
albumin. Sections were incubated for 1 hour at room temperature with the primary
antibodies. Sections were washed in TBS for 10 minutes and successively incubated
with secondary antiserum, biotinylated anti rabbit antiserum and streptavidine
reagent. Peroxidase activity was revealed using diaminobenzidine with copper
enhancement. Sections were counterstained, dehydrated, and mounted in DPX
(distrene, tricrecyl phosphate, xylene). For identification of neurons, antibodies
against marker proteins for neural perikarya, PGP 9.5 (protein gene product) was
applied. PGP 9.5 is a ubiquitin carboxy terminal peptidase which is abundantly
expressed by both peripheral and central nervous fibres and is present within the
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axoplasm. It is an excellent marker for axons, including small unmyelinated nerve







As stated in section 4.1, mechanisms which may be responsible for the early phase of
gallbladder emptying were examined. Early gallbladder emptying could be mediated
neurally in response to the anticipation of food; that is, there may be a cephalic phase of
gallbladder contraction effected by the vagus nerve. Alternatively, gastric distension
might stimulate release of hormones which act upon gastrointestinal motility. Thus
plasma CCK and gastrin concentration were measured in relation to gallbladder and
gastric emptying in a range of experimental situations.
6.2 Subjects and Methods
Two experiments were performed. The first examined the relationship between gastric
emptying and gallbladder contraction. The second examined putative mechanisms of
the early phase of gallbladder emptying.
6.2.1 Simultaneous measurement of gastric and gallbladder emptying
Seven subjects ( 5 males, aged 40-55 years) were recruited from medical staff. None
had a history of dyspepsia, peptic ulcer, gallstones, diabetes or thyroid disease. All had
a body mass index of less than 30 and none smoked. All volunteers tested negative for
Helicobacterpylori by the C14 Urea Breath test.
Gallbladder and gastric emptying were measured simultaneously following ingestion of
a test meal comprising a two eggs omelette (10.8g of fat and 147 kcal), eaten within 3
minutes. The omelette was labelled with 15 mBq of Tc"m before cooking and solid
gastric emptying was measured as described in section 5.6. Radioactivity over the area
of interest was measured at 10-minute intervals for 90 minutes. Gallbladder volumes
were measured by ultrasound scans at similar intervals following the meal.
6.2.2. Early gallbladder emptying
This was an open, within subject study involving a further group of 8 healthy
non-smoking male volunteers (age 27-37 years) recruited from medical and laboratory
staff.
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(1) Measurement of gallbladder emptying
Each volunteer was studied after an overnight fast on three separate mornings in
random order : (1) Fatty meal The test meal comprising a two egg omelette was eaten
within 3 minutes. (2)Modified sham feeding Volunteers were asked to chew and then
spit an omelette into a receptacle for a 3-min period. They were instructed not to
swallow the food and to rinse the mouth with water between each morsel. (3)
Gaseous distension Gallbladder volumes were measured during gastric distension
caused by ingestion of two sachets of effervescent powder (Carbex Granules, Ferring
Pharmaceuticals, U.K.). This compound is routinely used in double contrast barium
meal and one sachet is known to produce 250 ml of carbon dioxide.
During each phase of the study, gallbladder volumes were measured by ultrasound
scan. Measurements were taken at 10 minutes intervals for 30 minutes prior to
ingestion of food or effervescent powder. Subsequent measurements were taken at 5
minute intervals for 30 minutes, at 10 minutes intervals for a further 30 minutes and at
15 minute intervals for the last 30 minutes.
(2) Measurement of gut hormones
Blood samples were obtained from an intravenous catheter at the same time intervals as
ultrasound scan measurements. The samples were kept on ice; plasma was separated
within 30 minute and stored at -70°C for subsequent assay ofCCK and gastrin. Plasma
CCK and gastrin concentrations were measured as described in section 5.5.
(3) Statistical analysis
Measurements of gallbladder volumes and gut hormones were performed in
duplicates, and the means were noted. Gallbladder volume was expressed in
millilitre and as a percentage of fasting volume. Ejection fraction (EF) was
calculated by the formula :
[(fasting volume-gallbladder volume)/fasting volume x 100].
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Integrated CCK and gastrin concentrations for each individual volunteer were
determined by calculating the area under the CCK and gastrin concentration-time
curves after subtraction of basal values. Results for the group are expressed as
mean+SEM. Statistical analysis was performed by analysis of variance. Differences
with a two-tailed p<0.05 were considered significant.
The studies were approved by the Lothian Ethical Subcommittee for Medicine and
Oncology.
6.3 Results
6.3.1 Simultaneous gastric and gallbladder emptying
Mean serial postprandial gallbladder volumes and gastric emptying are depicted in
figure 6.1. Gallbladder emptying started immediately after ingesting the test meal and
preceded gastric emptying. Significant emptying of solids from the stomach started
after a mean lag period of 30+10 minutes. By this time, the gallbladder had emptied by
35.7+14%
6.3.2 Gallbladder emptying : early phase
There was no significant difference in mean fasting gallbladder volume + SEM on the
three different days. That for test meal alone was 22.9 ±2.1 ml, sham feeding was
22.7 + 3.6 ml and gaseous distension was 21.7 + 4.4 ml..
(1) Test meal
Fatty meal ingestion was followed by immediate gallbladder emptying at a mean rate
of 0.57ml/min, with an ejection fraction (EF) of 25% by 10 minutes (figure 6.2). Only
two subjects had an EF of less than 10% in the first 10 minutes. The initial phase of
gallbladder emptying was associated with increases in mean immunoreactive plasma
CCK concentrations from 6.2+0.9 ng/L to 10.1+3.2 ng/L. Mean plasma gastrin
concentrations also increased following the meal, from 26.3+4.7 to 31.5+6.2 ng/L
(figure 6.3).
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After a mean period of 25 minutes, the rate of gallbladder emptying slowed to
0.19+0.05 ml/min and this was associated with a second, more sustained rise of plasma
CCK concentrations to 9.5+1.5 ng/L and of gastrin to 34+5.4 ng/L. Mean integrated
CCK and gastrin concentrations were 237+70 ng/L and 974+297 ng/L respectively
(figure 6.5).
(2) Modified Sham Feeding
Gallbladder emptying did not occur in six of the subjects after the sham feed, and the
mean gallbladder volume of the whole group was unchanged by sham feeding (figure
6.2). Plasma CCK and gastrin concentrations remained at basal levels (figure 6.4).
However, in two subjects sham feeding stimulated gallbladder emptying with an EF of
at least 25% at 20 minutes in both cases (figure 6.6 and 6.7). In these subjects CCK
concentrations increased from 13 to 18 ng/L, but plasma gastrin concentrations did not
change (figure 6.6). Integrated CCK and gastrin concentrations for the whole group
were 39+13 ng/L and 59.6+31 ng/L respectively. The integrated concentrations of
CCK and gastrin were significantly less than the levels obtained after fatty meal (figure
6.5).
(3) Gaseous distension
No significant gallbladder emptying followed gastric distension and plasma CCK and
gastrin concentrations were unaltered throughout (figure 6.2 and 6.4). There was no
significant rise of integrated plasma CCK and gastrin concentrations (figure 6.5).
6.4 Discussion
This study confirmed that gallbladder emptying started before the onset of significant
gastric emptying of solids. Gallbladder emptying exhibited a biphasic emptying
pattern comprising a rapid early phase followed by a slower phase 366. The early phase
of gallbladder emptying was associated with increases in immunoreactive plasma CCK
and gastrin concentrations. In the majority of individuals modified sham feeding did
not provoke gallbladder emptying, but in two this did occur with EF ofmore than 25%
at twenty minutes and emptying was associated with increases of plasma CCK
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concentration. Gaseous gastric distension was not associated with gallbladder
emptying, nor with changes in plasma CCK and gastrin concentrations.
The stimulus for increased plasma immunoreactive CCK concentrations noted
immediately after eating is unknown, but it is reasonable to speculate that release of
CCK is responsible for the early phase of gallbladder contractions. The plasma
concentration achieved immediately after eating was above 10 ng/L, consistent with the
1QO
threshold plasma level of 1.5 pM previuolsy identified for gallbladder contraction
It is unlikely that entry of a proportion of the fatty meal into the duodenum stimulates
early release because the time course of gallbladder contraction is so rapid. Equally,
gastric distension by the test meal seems an unlikely stimulus for hormone release and
gallbladder contraction because the volume of the test meal was modest and because
gaseous distension failed to cause the gallbladder to empty or hormone concentrations
to rise. Gastrin is unlikely to be responsible for gallbladder contraction. It causes
gallbladder muscle contraction in some species, though much less potently than CCK 19
and not at all in man20.
We postulate several mechanisms for the early phase of gallbladder emptying and
release of CCK. This is illustrated diagrammatically in figure 6.8. There is intramural
plexus in gallbladders that contain cholinergic neurons supplied by the anterior branch
of vagus nerve 13. During the cephalic phase, it is possible that gallbladder contraction
could be stimulated by vagal cholinergic stimulation directly on gallbladder smooth
muscle. It is known that direct cholinergic stimulation by bethanechol produced
significant gallbladder emptying and cholinergic blockade with atropine diminished
27 28 • •
the gallbladder emptying responses to food and CCK ' . This effect of cholinergic
• • 29
blockade appeared to be mediated by a selective muscarinic M2 receptor . It is also
possible that vagal mechanism during the cephalic phase can stimulate the release of
CCK. CCK neurons are found in the myenteric and submucous plexus, and circular
muscle layers of the small bowel and colon 367. CCK neurons are abundant in the
coeliac plexus and vagus nerve 368.
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Like others an inconsistent cephalic phase of gallbladder emptying in response to sham
feeding was observed between individuals 333>334,369^ ma^ ^ue tQ y^^
cholinergic neural mechanisms as cholinergic blockade with atropine inhibits
gallbladder emptying in response to sham meals 333-370. Fisher et al 333 and Hansen et
al 3j4 also showed that atropine inhibited the cephalic phase of gallbladder emptying
although they did not measure CCK concentration during their studies. Whilst most
subjects did not exhibit gallbladder contraction following sham feeding, this did occur
in two of the eight volunteers. In these two subjects, plasma CCK but not gastrin
concentrations increased in association with gallbladder emptying. This could be due to
subject variation in the cephalic stimulation of CCK secretion as has been noted for
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pancreatic polypeptide release after sham feeding . It is unlikely that the rise in CCK
was due to inadvertent swallowing of food as the duration of sham feeding in this study
was only three minutes and there was no rise of gastrin concentration in these two
individuals to suggest entry of nutrients in the stomach.
It is possible that CCK is released in response to entry of nutrients into the stomach i.e.
gastric phase. Indeed gastropancreatic and gastrobiliary reflexes have been described
in dogs l45'372'j73 and man 366'369. This might be mediated by neural reflex sensitive to
intragastric nutrients and the gallbladder smooth muscle or be due to the action of
gastrointestinal hormones such as bombesin released in the stomach. Bombesin is
released by intragastric nutrients immediately after eating and is known to be a
stimulant for CCK release .
The threshold for CCK release by intraduodenal nutrient stimuli is not well
documented. It is possible that small amounts of swallowed food mixed with acid fluid
stimulated by gastrin, entered the duodenum causing CCK release before the detection
of labelled solid particles in the intestine. This issue was not examined by the current
study though Froehlich.et al in their study on a group of healthy volunteers showed that
with three different isocaloric meals, pure fat meal containing 25 g triglycerides
induced significantly higher CCK release compared to low fat ( 8 g ) or dextrose meals
(integrated CCK concentrations of 187+27 pM, 157+12 pM and 87+13 pM
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respectively). It is therefore unlikely though not conclusively excluded, for small
amounts of nutrients to flow into duodenum inducing significant CCK release as noted
in this study before significant gastric emptying was detected.
The pattern of CCK release following the test meal is therefore of considerable interest
(figure 6.3). Immediately after ingestion, plasma CCK concentration peaked and this
was associated with the rapid, early phase of gallbladder emptying. This may be due to
a combination of vagal activity (the cephalic phase) and gastric reflexes as nutrients
enter the stomach and stimulate hormone release. After the initial burst of release,
CCK concentration then slowly rises and plateaues, and this is associated with a
second, rather slower phase of gallbladder emptying. Presumably this occurs as a
consequence of food entering the upper small bowel, and stimulating CCK release.
In conclusion, the early phase of gallbladder emptying preceded gastric emptying of
solid food and was associated with elevation of CCK concentrations. Cephalic vagal
stimulation with modified sham feeding stimulated gallbladder emptying with CCK
release in some individuals. In the majority of individuals, sham meals and gaseous
gastric distension did not provoke either gallbladder emptying or CCK release. We
speculate that the early phase of gallbladder emptying could be due to a combination of
vagal activity and gastric reflexes in response to intragastric nutrients that stimulates
CCK release and gallbladder contraction.
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Figure 6.1 Gastric emptying and gallbladder emptying fMeans+SEM) after test meal.
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Figure 6.3. Gallbladder emptying and plasma CCK and gastrin concentrations
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Figure 6.5. Integrated plasma CCK and gastrin concentrations (Means+SEM) during
the different test procedures.
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Figure 6.6 Average of rate of gallbladder emptying and plasma CCK concentration in
two individuals who responded to sham meals.
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—No gallbladder contraction to sham feeding
—■— Gallbladder contraction to sham feeding
Figure 6.7 Gallbladder emptying in response to sham feeding for each volunteer.
Cephalic phase : mediated
by cholinergic vagal
pathway
Figure 6.8. Diagrammatic representation of postulated mechanisms for early release of
CCK and gallbladder emptying.
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CHAPTER SEVEN
NITRIC OXIDE AND GALLBLADDER EMPTYING
7.1 Introduction
In this study the effects of NO donors and L-NMMA were defined in isolated
gallbladder muscle strips, and gallbladders were stained for the presence of NOS with
neuronal NOS specific antibody. Subsequently these agents were infused systemically
during measurements of postprandial gallbladder emptying in a group of healthy
volunteers.
7.2 Methods
7.2.1 in vitro study -
As described in section 5.4, bovine and human gallbladders were studied. Strips were
incubated in Kreb's solution, and the effects of GTN, SNP, and L-NMMA upon muscle
contraction were defined.
Ten fresh bovine gallbladders were obtained from a local abattoir and transported in
cooled Kreb's solution. They were placed in a Petri dish under cooled oxygenated
Kreb's solution and four muscle strips (10 mm long and 2-3 mm wide) were obtained
from each gallbladder. Experiments were usually started within one hour but tissues
were still found to be viable when used up to four hours after removal. Strips of gall
bladder were mounted for isometric tension recording in four separate 10ml organ
baths containing Kreb's solution at 37°C, continuously bubbled with C>2:C02
(95%:5%). The basal tension was adjusted to 2 g which was the tension that achieved
maximum degree of contraction in response to 50 mmol potassium chloride in
preliminary study. Changes in tension were monitored by isometric force transducers
connected to a Macintosh computer using MacLab Chart V3.2 software. The strips
of muscle were equilibrated for at least one hour before the start of each experiment.
The muscle strips were stimulated with CCK (Cholecystokinin, Ferring
Pharmaceuticals, Malmo, Sweden) at concentration 5xlO~9M to test for viability and
to achieve contraction. In preliminary study with cumulative concentrations of CCK,
we determined the EC50 at 5xlO"9M and this concentration was used in further
experiments. Once maximum tension was achieved, GTN (Glyceryltrinitrate,
Nitrocine, Schwarz Pharma, UK. Final bath concentration= 5xl0°M), SNP (Sodium
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nitroprusside, Sigma, St Louis, USA. 10"3 M) and 100 p.1 Kreb's solution as control
was added into each bath. The effect of inhibition of NOS upon muscle contraction
was examined by adding L-NMMA (Calbiochem-Novabiochem, U.K. Cumulative
concentrations from 2.0 to 8.0 x 104 M) to muscle strips in Kreb's solution under
basal, unstimulated conditions.
The experiment was repeated using two normal human gall bladders removed at the
time of pancreatic resection (Whipple's surgery). Immediately after removal,
segments of gall bladder (2 cm long and 2 cm wide) were taken from the body and
placed in a vacuum flask containing cooled pre-oxygenated Kreb's solution. Muscle
strips were then studied in an identical manner to that described for the bovine
gallbladder.
7.2.2 Immunohistochemistry of nitric oxide synthase
Ten archival gallbladders removed at laparoscopic cholecystectomy were subjected
to immunohistochemical staining for NOS as described in section 5.7 In addition,
two gallbladders were prepared by fresh frozen section immediately after
cholecystectomy. Two colonic specimens and a normal appendix were prepared as
positive controls. The colonic specimens were obtained from normal colon at least 5
cms from surgically removed carcinomata. Specimens were also stained with
neuronal marker, PGP 9.5.
7.2.3 in vivo study -
(1) Subjects
Six young, healthy male volunteers ( aged 23-31 years ) were recruited after informed
consent. All had a body mass index of less than 30 and none had diabetes,
hyperthyroidism, liver disease or gallstones.
(2) Method of infusion
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SNP (Faulding Pharmaceuticals pic, U.K.) and GTN (Nitrocine, Schwarz Pharma,
UK) were infused as NO donors. Hydralazine (Ciba-Geigy, U.K.) was infused as a
hypotensive control agent to ensure that any differences in gallbladder motility
following SNP and GTN were not due to the nonspecific effects of vasodilation and
hypotension. Finally, gallbladder emptying was studied during an intravenous infusion
of the NOS inhibitor, L-NMMA (Calbiochem-Novabiochem, U.K.).
Each volunteer was studied after an overnight fast on five separate days in random
order:
1) After a test meal consisting of a two egg omelette containing 10.8 g of fat
and 147 kcal, consumed within 3 minutes. Intravenous normal saline (50 ml hourly)
was infused as placebo.
2) After test meal and intravenous infusion of GTN increasing by increments of
1, 2, 5 and 10 mg/hour.
3) After test meal and intravenous infusion of SNP 0.5 micrograms/kg/min
initially, then increased by 0.5 microgram/kg/min.
4) After test meal and intravenous infusion of hydralazine, 100
microgram/min, increasing by 50 microgram/min.
5) After test meal and intravenous infusion of L-NMMA, 3 mg/kg over 20
min. Previous study had shown that this dose of L-NMMA was well tolerated and
increased mean arterial pressure by 10% 164.
After insertion of an indwelling intravenous catheter for blood sampling, volunteers
were rested for at least 30 minutes until a stable resting blood pressure and heart rate
were obtained. Infusion rates of the three hypotensive agents were adjusted at 15
minutes intervals until a decrease ofmean arterial blood pressure of at least 10% or an
increase of heart rate by 20% was achieved. Infusions of these agents or placebo were
started at least an hour before the test meal and maintained until the end of the
experiments. L-NMMA infusion was started 20 minute before the meal. The
ultrasonographs was blinded to the infusates which were covered in aluminium foil.
Blood pressure was measured at 15 minute intervals and heart rate was continuously
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monitored by finger plethysmography using Finapres BP monitor machines (Ohmeda,
Japan).
(3) Preparation of drugs
L-NMMA was purchased in ampoules of 200 mg which was constituted with normal
saline to 50 ml. The reconstituted solutions were used within one hour after
preparation. GTN was used unchanged at manufacturer's preparation of lmg/ml in
ampoule of lOmg. SNP was purchased in ampoule of 50 mg and this was diluted to 50
ml with 5% dextrose. The constituted solution was immediately covered with
aluminium foil and used within three hours. Each 50 mg ampoule of hydralazine was
dissolved to 50 ml with normal saline and used within three hours.
(4) Measurements of gallbladder volume
Measurements were taken before infusion (fasting volume) and just before ingestion of
the fatty meal (pre-ingestion volume). The test meal was then ingested and for the next
30 minutes, gallbladder volumes were measured at 5 minute intervals. Subsequent
measurements were taken at 10 minute intervals for a further 30 minute and at 15
minute intervals for the last 30 minutes. Blood pressures and pulse rates were
monitored throughout the study at the same frequency as measurements of gallbladder
volumes.
(5) Measurements of gut hormones
Blood samples were obtained from an intravenous catheter at the same time intervals as
ultrasound scan measurements. The samples were kept on ice and plasma separated
within 30 minute and stored at -70°C for subsequent assay of CCK and gastrin. Gut
hormones were measured by standard radioimmunoassay as described in 4.5.
(6) Statistical analysis
Measurements of gallbladder volumes and gut hormones were performed in
duplicate, and the mean of these two measurements was used for further analysis of
results. Gallbladder volume was expressed in millilitre and as a percentage of fasting
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volume. Ejection fraction (%) was calculated by [ (fasting volume-volume at time
't')/fasting volume x 100].
Integrated CCK and gastrin concentrations for each individual volunteer were
determined by calculating the area under the CCK and gastrin concentration time
curves after subtraction of basal values. Results for the group are expressed as
mean+SEM. Statistical analysis was performed by analysis of variance. Differences
with a two-tailed p<0.05 were considered significant.
For the in vitro experiment, mean tension was recorded in gram and results expressed
as mean+SEM. Changes in tension with different reagents were compared by paired
'f test.
The studies of gallbladder contraction were approved by the Lothian Ethical
Subcommittee for Medicine and Oncology.
7.3 Results
7.3.1 in vitro study of gallbladder contraction
Some strips from bovine gallbladders exhibited spontaneous tonic and phasic
muscular activity in the absence of CCK; in others contraction only occurred after the
addition of CCK. Mean basal resting tension was 2.5+0.4 g (6 specimens) and this
increased to 4.2+0.6 g after CCK. Subsequent addition of 100 pi of Kreb's solution
did not alter tension. In contrast GTN and SNP immediately reduced mean tonic
activity to 1.3+0.1 g (p<0.01) and 1.4+0.2 g (p<0.01) respectively; addition of both
drugs also abolished phasic contractions for approximately 1 minute (figure 7.1).
Figure 7.2 shows a typical polygraph showing contractile activity of muscle strips
and abolition of tone and phasic activity after addition of GTN and SNP. L-NMMA
increased mean tonic contraction from 2.7+0.2 g (4 specimens) to 3.6+0.3 g
(p<0.05). The maximum effect was associated with concentration of L-NMMA of
5x10"4M.
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In the human gallbladders, CCK increased mean basal tension from 1.2 g to 1.7 g.
Tonic and phasic activity were inhibited by GTN and SNP. Both agents decreased
mean basal tension to under 1.0 g. L-NMMA increased mean tension from 1.1 to
1 5 cr
7.3.2 Immunohistochemistry
Positive staining for PGP at dilution of 1/600, was obtained on the myenteric and
submucosal plexus of colon and appendix. Staining was obtained in both the
neuronal cell bodies and fibres, and in fibres within the smooth muscle. In
comparison with colon and appendix, gallbladders were more sparsely populated
with nerves although ganglion cells and nerve fibres could be easily identified in all
layers of the gallbladder wall with PGP (see plate 7.1). Large trunks in the
gallbladder subserosa and slender filaments in the mucosa were both strongly
positive for PGP. Neurons were also seen in the lamina propria.
NOS staining was identified in the myenteric and submucosal plexus of both colonic
and appendix sections with antisera to NOS at 1/400 concentration (see plate 7.2).
Neuronal NOS immunoreactivity was observed consistently in all the ganglion cells
and nerve fibres of plexus myentericus and most of the nerve fibres of the circular
muscle layer. Immunoreactive neurons were much less conspicuous in the
longitudinal muscular layer. This concentration of NOS antiserum was therefore
used for subsequent staining of gallbladders. No NOS immunoreactive neurons
could be identified in the gallbladder although as in the colon, background
immunoreactivity was visible in erythrocytes and platelets (see plate 7.3). Similar
negative staining was observed in both archival and fresh frozen specimens.
7.3.3 in vivo study
The median dose of drugs infused is shown in table 7.1. During infusions with the
three hypotensive agents, there was a significant decrease in mean blood pressure and
an increase of heart rate. All of the subjects also experienced headache and facial
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flushing but none developed nausea or vomiting. There was no significant change in
the fasting gallbladder volume after one hour of infusion (table 7.2).
The rates of gallbladder emptying during infusions with placebo, hydralazine and
L-NMMA are shown in figure 7.3. There were no significant differences in the rates
of gallbladder emptying during infusion with these three agents. Figure 7.4 shows
the rate of gallbladder emptying during infusions with GTN, SNP and placebo.
During infusion with both GTN and SNP. there was significant impairment in
gallbladder emptying. At the end of the study period, the ejection fraction was 50%
compared with the ejection fraction in excess of 80% during infusion with placebo.
There was no significant difference in the integrated CCK and gastrin concentrations
during the post-prandial period with all the different infusions (figure 7.5). The
concentration profiles of CCK and gastrin during the post-prandial period were very
similar.
7.4 Discussion
In isolated bovine and human gallbladder muscle strips, CCK stimulated tonic and
phasic activity was inhibited by the NO donors GTN and SNP. In contrast the NOS
inhibitor L-NMMA increased muscle tone. These in vitro effects correspond to in
vivo findings of impaired post-prandial gallbladder emptying during infusions with
GTN and SNP. This inhibition was not due to hypotension as hydralazine did not
cause similar inhibition. Post-prandial CCK and gastrin release were not influenced
by infusions of the NO donors. It is therefore reasonable to conclude that the NO
pathway may be involved in gallbladder motor function.
The in vitro observations described in these studies are consistent with those of
Mourelle et al, who showed that NANC pathway may influence gallbladder function
in guinea pigs. In this study, resting gallbladder pressure of anaesthetised guinea
pigs and its CCK induced contractions were enhanced by inhibition of NOS with
L-NAME; this effect of L-NAME could be reversed by L-arginine 262.
Whilst the in vivo study showed that GTN and SNP significantly impaired
post-prandial gallbladder emptying, fasting gallbladder volumes were unaffected by
these infusates. This is probably because the fasting gallbladder is maximally
dilated. In contrast to the observation by Konturek et al 267, L-NMMA did not cause
reductions in fasting gallbladder volumes or accelerated gallbladder emptying. The
in vitro study with isolated muscle strips showed that under basal condition,
L-NMMA had a small but significant excitatory effect on gallbladder contraction
although the increase in tone contraction was much smaller than that induced by
CCK. The reason for this discrepancy is unclear but it is possible that the increase in
tone and contractility caused by L-NMMA during the in vitro experiment was due to
stimulation of cNOS (endothelial) during preparation of the muscle strips for the
experiment. Acetylcholine, bradykinin or shear stress can cause influx of Ca2+ into
endothelial cells and results in NO synthesis 274. Bacterial lipopolysaccharides in the
Kreb's solution is known to induce the NOS in vascular tissues in vitro l79. On the
other hand, the lack of effect on gallbladder motility during in vivo experiment can be
attributed to the dose and method of infusion of L-NMMA. L-NMMA was only
infused to the volunteers before meals in contrast to the study by Konturek et al 267 in
which it was continuously infused throughout the post prandial period.
Both SNP and GTN release NO by pathways which are independent ofNOS and the
L-arginine : NO pathway j74. Unlike L-arginine, they do not stimulate release of
glucagon and somatostatin which may have secondary effect on gallbladder
emptying 262. The impaired post-prandial gallbladder emptying by GTN and SNP
was not associated with any effects upon the post-prandial release of gastrin and
CCK. Therefore the inhibitory effects of these infusates upon gallbladder emptying
were not due to changes in the release of these gastrointestinal hormones.
Furthermore, the impairment of gallbladder emptying was not a secondary effects of
hypotension as hydralazine infusion did not induce similar inhibition despite
inducing similar degree of hypotension.
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It is possible that the effects of the NO donors upon gallbladder emptying were
indirect and mediated through delayed gastric emptying. Sublingual GTN and
intravenous L-arginine have been shown to delay gastric emptying in a group of
healthy volunteers after a liquid _!6 or a semi solid meal 375. In this study gastric
emptying was not measured, but the observation that plasma gastrin and CCK
concentrations following the meals were similar during each study day suggest that
this was not an important factor.
The presence ofNANC inhibitory nerves and the role ofNO as a neurotransmitter for
gallbladder motor function are unclear. For example, Li et al reported that
transmural EFS had no effect upon gallbladder muscle contraction in the prairie dog
o-j/r t ...
. Furthermore. Feeley et al failed to demonstrate NANC activity in isolated human
gallbladders which were subjected to EFS following adrenergic and cholinergic
blockade 265. In contrast, McKirdy et al were able to detect NANC inhibitory
responses in isolated human gallbladders using a shorter pulse width of EFS and
noted this was abolished by L-nitroarginine . L-arginine reversed the effects of
L-nitroarginine, suggesting a role for NO in NANC neurotransmission in the human
gall bladder.
To clarify this controversial area, attempts were made to stain the synthetic enzyme
NOS in human gallbladder muscle. Control tissues (colon and appendix) stained
positively for neuronal NOS antisera on nerve cell bodies and fibres. Background
immunoreactivity with NOS within erythrocytes and platelets was also noted in both
the control tissues and gallbladder sections. However, NOS could not be
demonstrated on nerve cell bodies and fibres of archival and fresh human
gallbladders. That nerve bodies and axons were present within these specimens, was
confirmed by positive staining for PGP which is known to be a reliable marker for
axons 36~\ Similar observations of background immunoreactivity with vascular
tissues have been reported by Springall et al 287 with antibodies to rat brain NOS.
The antibody was similar to the one used in the current study in that they were both
raised in rabbits to the carboxyl-terminal peptide 58, corresponding to amino acids
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1409-1429 of rat brain enzyme. It is likely that NO activity in homogenates of
guinea pig gallbladders 262 were due to activity within vascular rather than neuronal
tissues.
The role of NO may be important in chronic cholecystitis and could account for the
impaired motility in this disease. Increased levels of inducible NOS were found in
inflamed gallbladders and immunohistochemistry showed localisation of NOS in
macrophages 126. It is theoretically possible that during chronic cholecystitis, the
generation of NO by the inflammatory process locally could inhibit gallbladder
smooth muscle contraction.
In conclusion, pharmacological doses of exogenous NO donors impaired
postprandial gallbladder contraction in vivo and relaxed contraction of isolated
muscle strips. However, it is unlikely that NO is the neurotransmitter for NANC
innervation in the gallbladder as its synthetic enzyme could not be identified in either
gallbladder nerve bodies or fibres.
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Table 7.1 Change in mean blood pressure and heart rate with the different infusions.
Drug Median Dose Mean blood pressure+SEM Mean heart rate+SEM (per
(mmHg) minute)
Pre-infusion Post-infusion Pre-infusion Post-infusion
GTN 60 pg/minute 76+2 67+2* 60±4 71±5*
SNP 0.5pg/kg/min 76+2 65+3* 55+3 70+6*
Hydralazine 100 pg/min 70+3 61+1* 57+3 61+4*
L-NMMA 3 mg/kg 70±2 81+3* 60+3 51+3*
Placebo 3 ml/min 75±2 75+2 55+2 57±3
* p<0.05 (paired student t test)
Table 7.2. Mean fasting and pre-ingestion gallbladder volumes ("mD+SEM.
Fasting Pre-ingestion p-value*
GTN 18+3 20+3 NS
SNP 21+4 21+4 NS
Hydralazine 22+3 20±3 NS
L-NMMA 21+3 18+3 NS
Placebo 19±2 20±2 NS
* paired student t test
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Figure 1.2 Polygraph shows muscular contractile activity and abolition of tone and





































Figure 7.4 Gallbladder emptying during infusions with GTN. Sodium nitroprusside
and placebo.
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Figure 7.5 Integrated CCK and gastrin concentrations over 90 minutes.
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Plate 7.1 Staining of ganglion cells and nerve fibres with PGP in gallbladder wall.
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Plate 7.2 NOS staining in the myenteric and submucosal plexus of colonic ("top
plate) and appendix (bottom plate)
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Plate 7.3 No NOS staining was obtained in the gallbladder neurones ftop) though
background immunoreactivity was visible in erythrocytes and platelets (bottom').
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CHAPTER EIGHT
NITRIC OXIDE AND THE SPHINCTER OF ODDI
8.1 Introduction
Delivery of bile into duodenum is controlled by hepatic bile secretion, gallbladder
contraction and the SO. CCK is believed to be responsible for post-prandial
gallbladder contraction and SO relaxation. Recent studies have shown that the effect
of CCK upon the SO is mediated through stimulation of the nonadrenergic
noncholinergic (NANC) nerves 10 and nitric oxide (NO) is an important element of
this pathway 20'-203.
There have been few studies on the effect ofNO on the function of the SO. Slivka et
al localised the presence ofNO synthase (NOS) in nerve fibres and bundles of human
SO and demonstrated that topical application of iS-nitroso-JV-acetylcysteine (SNAC),
a NO donor, inhibits SO motility. However, SNAC needs to be freshly prepared, is
not stable over a prolonged period of time and is not widely available. The aim of
the present study was to examine the effect of glyceryl trinitrate (GTN, Nitrocine,
Schwarz Pharma, U.K.), a form of NO donor that is commercially available, on SO
motility.
8.2 Subjects and Method.
8.2.1 Patients characteristics
Nineteen patients (17 females; median age 41, 29-61 years) undergoing routine SO
manometry for investigation of upper abdominal pain were examined. Seventeen
patients underwent manometry for investigation of post-cholecystectomy pain
occurring one to five years after surgery. The other two patients had intact
gallbladders. None of the patients was on regular medication with nitrates or
calcium channel blocker drugs. All of the patients had normal abdominal
ultrasound scans and ERCP prior to manometry.
8.2.2 Sphincter of Oddi manometry
After an overnight fast, patients were sedated with 5-10 mg of intravenous
midazolam. SO manometry was performed with a standard triple-lumen
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polyethylene manometric catheter by the water perfusion technique as described in
section 5.2.2.
After recording duodenal pressure, which was taken as the zero reference, the papilla
was cannulated and the catheter was withdrawn across the SO in 2 mm increments
using the black marks on the catheter as a guide. Recordings were obtained for at
least 60 second at each station. After two such pull-throughs, the catheter was
repositioned so that the proximal and middle channels were recording phasic SO
contractions. The most distal channel was therefore located just outside the papilla.
Patients were randomised into three groups. The first group of patients received
topical application 10ml normal saline; the other two groups received GTN at either 5
mg (0.5 mg/ml with volume of 10 ml; GTN 5) or 10 mg(lmg/ml with volume of 10
ml; GTN 10). The distal channel was disconnected from the perfusion system and the
drug solutions were then infused into the channel over 1 minute. Recording was
started immediately at the end of drug infusion and continued for 5 minutes.
8.2.3 Analysis of manometric recordings
Manometric tracings were coded and analysed by an experienced observer who was
blinded to the types of infusion.
8.2.4 Statistical analysis
All data are reported as mean+SEM unless otherwise stated. Paired Student's tests
were used to compare variables before and after injection. Differences with P values
of less than 0.05 were considered significant.
The studies were approved by the Lothian Ethical Subcommittee for Medicine and
Oncology.
8.3 Results
Five patients were randomised to saline injection; two groups of seven patients were
each randomised to either 5 mg or 10 mg GTN.
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The baseline results of SO motor activity are presented in table 8.1. The means of all
the motor variables were within normal limits as defined by previous studies using a
similar perfusion technique in healthy volunteers 346-;,;'0'353. Two patients were found
to have SO dysfunction 377. One patient exhibited a basal SO tonic pressure of 90
mmHg accompanied by tachyoddia (frequency of 12 contraction per seconds); she
was randomised to GTN 5 mg. The second patient who was randomised to 10 mg
GTN was also found to have tachyoddia, but had normal tonic SO pressure.
There was a non-significant increase in basal SO tonic pressure, amplitude and
frequency of phasic activity after injection of 10ml normal saline. In contrast, mean
tonic SO basal pressure and all the variables of phasic SO activity significantly
diminished after injection with 5mg and lOmg of GTN; specifically phasic
contractions became significantly less frequent, were shorter in duration and had
decreased amplitude (figure 8.4 for SO manometry tracing). Consequently the
motility indices fell from 312+35 mmHg sec to 39.5+19 in the group who received
GTN 5 mg and from 462+125 to 57+27 mmHgsec in the higher dose GTN group
(figure 8.1, 8.2 and 8.3). These effects were seen both in patients who had normal
SO function and in those who had abnormal SO motility.
The duration of GTN inhibition on SO was 2 minutes. Although duodenal motility
was not quantitated, video recording also showed cessation of contractility.
8.4 Discussion
Topical application of GTN but not normal saline significantly inhibited SO tonic
and phasic activity. Five and 10 mg ofGTN showed similar efficacy with a duration
of approximately 2 minutes in both cases.
Complex neurogenic and hormonal mechanisms are involved in the control of the SO
muscle tone and motility. Ingestion of a meal 60 and injection of CCK 61 produced a
decrease in SO basal pressure and amplitude and reduced the frequency of phasic
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contractions, thereby facilitating bile flow into the duodenum. The inhibitory effect
of CCK is believed to be mediated through NANC inhibitory nerves 10. NO has been
96Q 970 979 9AQ 97Q
demonstrated to control SO motility in animals ' ' ' ' and the presence of
97*2 "7*70 97Q
NOS has been confirmed in the SO neurons of rabbits ' ' . In humans,
involvement of NO in SO motility is suggested by the findings of NOS in nerve
bundles and fibres by NADPH diaphorase immunohistochemical staining and,
furthermore topical application ofSNAC inhibits SO motility 273.
In humans, sublingual GTN has been found to be effective in improving
post-cholecystectomy pain associated with SO dysfunction although side effects
limited its therapeutic potential 3S0. Staritz et al demonstrated that sublingual GTN
lowered SO basal pressure and contraction amplitude during SO manometry. In
contrast to findings from this current study, SO frequency was not inhibited but this
difference could be attributed to drug dosage and mode of administration 271. Staritz
et al subsequently showed that common bile duct stones between 6-12 mm in
diameter could be removed from an intact papilla after GTN-induced SO relaxation
272"
~. Recently, sublingual GTN spray was shown to facilitate papillary cannulation
during ERCP 381.
Topical application of GTN could be of clinical application during ERCP as it
inhibits both duodenal and SO motility. When administered orally, sublingual GTN
can cause headache and may cause hypotension. Local administration to the papilla
was not associated with systemic effects and high volumes can be targeted to the SO.
This may have advantages over the administration of systemic drugs. It would be
helpful in inhibiting duodenal and SO motility in patients who are intolerant of
buscopan or glucagon during ERCP. It could also facilitate extraction of small
stones from the biliary tree without resort to sphincterotomy or papillary balloon
dilatation. However, its duration of action is relatively short and this may limit its
clinical application.
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In summary, topical application of GTN inhibited SO tonic and phasic contraction.
This mode of GTN delivery may be of clinical application during ERCP cannulation
and stone extraction and should be examined in clinical trials.
150
Table 8.1 Baseline manometric motor variables fMeans+SEM) before application of
drugs.
Saline GTN5 GTN 10
(n=6) (n=7) (n=7)
Mean Duodenal pressure (mmHg) 25.7±4.4 22.7+3 22.5+3.4
Mean CBD pressure (mmHg) 15.1+3.8 6.2+4.3 10.4+2.7
SO motor characteristics
Basal (mmHg) 31.1±1.8 16.7+2.7 33.2+4.3
Amplitude (mmHg) 108.8+26 77.8±7 84+18
Duration (seconds) 5.6+1.4 4.8+0.3 5.4±1.6
Frequency (per minutes) 5.7+1.8 4.4+0.3 7.2±1.5
Motility Index (mmHg sec) 496±118 312+35 462+125
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Figure 8.1 Change in basal SO tonic contraction and and frequency of phasic








































Figure 8.2 Change in amplitude and duration of phasic contractions (Means+SEM)
with the different infusions.
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Motility Index




















Figure 8.4. SO manometry tracing during infusion with GTN ("condensed to paper
speed of lcm/min). There was abolition of phasic activity recorded at the proximal and








Since its introduction in 1987, laparoscopic cholecystectomy (LC) has become the
standard treatment for symptomatic gallstone disease. The advantages of LC over
•>o") -301
open surgery are well documented .As discussed in chapter 4, no study has
.prospectively examined the post-cholecystectomy syndrome in relation to LC.
9.2 Patients and Methods
9.2.1 Patients' characteristics
100 consecutive patients admitted for LC between June 1994 to June 1995 were
recruited into the study. The diagnosis of cholelithiasis was confirmed by
ultrasonography in all cases. Patients were excluded if open cholecystectomy had
been planned or they were unable to cooperate in answering the questionnaires.
Indications for cholecystectomy and details of investigations performed prior to
surgery were obtained from medical notes.
9.2.2 Questionnaires
The symptom profile of the patients was evaluated by a standard questionnaire
administered by the author of this thesis (see appendix two) which examined
characteristics of pain (site, duration, frequency, quality, periodicity, precipitating
and relieving factors), other dyspeptic symptoms (nausea, vomiting, heartburn, food
intolerance and early satiety) and colonic symptoms (bloating, constipation,
diarrhoea). A previous history of hysterectomy and of psychiatric disturbances were
also evaluated. Questionnaires were administered to patients before surgery and at
least six months postoperatively. Patients were followed up in routine outpatient
review or by telephone interview. Their notes were reviewed for operation details,
postoperative morbidity, complications, and gallbladder histology.
LC was done as a four-trocar technique with electrocautery dissection by four
consultant surgical teams.. Intraoperative cholangiography was not routinely
performed. Patients with a history of jaundice, abnormal liver function tests, dilated
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common bile duct and pancreatitis underwent pre-operative ERCP and
sphincterotomy.
9.2.3 Statistical methods
Logistic regression analysis was performed to develop a model to predict pain after
LC. Simple comparisons of pre-operative symptoms between patients with post-LC
pain and those with successful outcome were performed (chi-squared p<0.05).
Significant factors (chi-squared p<0.05) were then entered into the logistic multiple
regression to construct a classification table.
Analysis of the associated symptoms was subdivided into dyspeptic and colonic
symptoms. Gallbladder histology was classified as normal, mild (mild chronic
infiltrate confined to lamina propria), moderate and severe (changes of cholecystitis
with severe acute and chronic inflammatory infiltrate, fibrosis and atrophy of
gallbladder wall).
The studies were approved by the Lothian Ethical Subcommittee for Medicine and
Oncology.
9.3 Results
9.3.1 Incidence of post-cholecystectomy pain
Three patients were excluded from the final analysis because the planned LC was
converted to open surgery. One patient had an empyema of the gallbladder and two
patients had dense adhesions. The remaining 97 patients were all successfully
followed up. No patients were excluded from the study because they were unable to
answer the questionnaire.
There were 19 males (20%) and 78 females (80%). The median age was 50.9 ( range
19-85) years. There was one complication each of biliary leak and bleeding. Two
other patients reported new onset of diarrhoea after LC. Thirteen patients (13%)
reported pain similar to that present before surgery and were defined as the
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'symptomatic group'. Patients who became pain free were defined as the
'asymptomatic group". All of the patients with post-cholecystectomy pain had
normal postoperative liver function tests and ultrasound scans; five patients had a
normal ERCP. Two patients had Helicobacter pylori positive duodenal ulcer disease
on gastroscopy. Symptomatic reliefwas obtained after eradication of the organism.
9.3.2 Preoperative characteristics
Indications for surgery and duration of symptoms are shown in table 9.1. Patients
underwent LC because of either chronic biliary pain or complicated gallstone disease
(acute cholecystitis, cholestatic jaundice or pancreatitis).
The majority of patients complained of upper abdominal pain (either epigastric or
right hypochondrium) (table 9.2). The duration and frequency of pain, the quality
and periodicity of pain were equally distributed in those who were asymptomatic and
symptomatic after LC. The prevalence of preoperative dyspeptic and colonic
symptoms is shown in table 9.3. The common dyspeptic symptoms were nausea
(60%), food intolerance (54%) and heartburn (30%). The majority of patients noted
fatty food intolerance. Of the colonic symptoms, bloating (50%) was the most
common.
The thirteen patients who continued to complain of pain following LC differed in
several respects from those who had a successful outcome. All but one of the
thirteen patients had a history of chronic biliary pain, and only one underwent
surgery because of acute cholecystitis (p<0.05, table 9.1). These patients had also
been subjected to more pre-operative investigations (gastroscopy or barium enema)
than those with a successful outcome (p<0.05, table 9.4). Previous hysterectomy
was not commoner in those with post-cholecystectomy pain. The majority of
patients who had a successful surgical outcome had histological evidence of
moderate or severe cholecystitis (64%), whilst the group with persistent pain usually
had normal histology or mild changes of cholecystitis (77%).
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As shown in table 9.3 and 9.4, bloating (p<0.001), constipation (p<0.05) and
previous or current consumption of antidepressant drugs (p<0.001) were significantly
commoner in the poor outcome group after analysis with chi-square statistics.
Psychiatric medications was defined as either current or previous medications with
antidepressant or anxiolytic drugs. Eight patients were taking psychiatric drugs (6 on
antidepressants, 2 on anxiolytics) at the time of surgery. However, logistic
regression analysis showed that only bloating and consumption of antidepressant
drugs were significantly associated with PC pain. With these two variables, a
classification table (table 9.6) was produced which could predict the outcomes of
pain free and persistent pain after surgery with 95% and 65% accuracy respectively
9.3.3 Postoperative characteristics
This is shown in table 9.5. Heartburn was not cured by LC although most patients
did not feel that this was a failure of cholecystectomy as they did not expect
heartburn to be relieved by surgery. Heartburn did not develop six months after
cholecystectomy. The cure rates for nausea and early satiety were in excess of 80%.
The reported incidence of nausea, vomiting and early satiety after surgery was
largely confined to patients who continued to experience pain after surgery. The
incidence of food intolerance was also low after LC but the majority of patients
continued on low fat diet after surgery.
9.4 Discussion
The incidence of post-LC pain was 13%. Preoperative abdominal bloating and use of
psychiatric drugs were significantly more common in these patients.
Studies that have assessed symptomatic outcome after open cholecystectomy have
given varying results. Ros and Zambon evaluated 93 patients two years after
1AO
cholecystectomy . Only 53 patients were completely symptom free. Konsten et al
309 followed up over 300 Dutch patients through postal questionnaires to their general
practitioners at a median interval of 10 years after cholecystectomy and reported
symptoms in 18%. Gilliland and Traverso followed up over 600 patients for a mean
160
follow up period of 45 months and found that 88% of patients had complete
nil
symptomatic relief after cholecystectomy . Patients with symptoms associated
with gallstones such as bloating, nausea and vomiting, but without the pain of biliary
colic were less likely (75%) to obtain symptom relief from cholecystectomy than
those with biliary colic. Around 1% of patients reported occasional diarrhoea.
Dyspepsia was the most common residual symptom after cholecystectomy, occurring
in 32 percent.
The reported varying incidence of the post-cholecystectomy syndrome can be
ascribed to the varying methods of evaluation, wording of questionnaires, and patient
case mix. Abdominal pain, heartburn, nausea, flatulence and other dyspeptic
symptoms are variously recorded and words such as dyspepsia and flatulence mean
many different things to different patients.
There have been few studies which have examined symptoms following LC. In a 3-
month follow-up of 52 patients, Peters et al reported that 77% of patients considered
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their symptoms to be cured by the procedure . In a comparative study of open and
LC, Vander Velpen et al reported that 95 percent of their patients thought that they
had obtained overall symptomatic improvement313. Qureshi et al performed analysis
of patients' perceptions of postoperative symptoms and global satisfaction 314. They
noted that 25% of patients complained of more than two symptoms postoperatively
but 84% considered the procedure to be a complete success. In a study of an earlier
cohort of patients from the same institution as the current study, Wilson and
Macintyre evaluated symptomatic outcome of 115 patients a year after laparoscopic
cholecystectomy and compared the outcome with 200 patients who had undergone
the open procedure. Over 90% of patients in both groups considered the procedures
to be successful in achieving symptomatic relief 315. McMahon et al reported over
90% of patients were improved after the operation 385. None of these studies
assessed patients symptoms in prospective manner i.e. only patients' postoperative
symptoms were evaluated and patients were either expected to list 314 0r their case
notes were reviewed for preoperative symptoms.
161
The incidence of post-cholecystectomy pain reported in this series is similar to that
reported for open cholecystectomy jllbut is higher than that reported by Wilson and
TIC
Macintyre . These authors found that 94 percent of patients considered the
operation to have cured or improved their symptoms and only 6.6 percent
complained of having abdominal pain every day or most days following
cholecystectomy. This may be because 34 percent of patients in their series had
acute cholecystitis compared to 20% in the current series and this higher proportion
may help to account for the better results 3I\
Patients with atypical biliary pain usually underwent extensive upper gastrointestinal
or colonic investigations before being referred for surgery. Despite this cautious
approach, two patients with post-cholecystectomy pain were subsequently found to
have Helicobacter pylori associated duodenal ulcer disease. It is noteworthy that
only one patient with post-cholecystectomy pain arose from the group with
complicated gallstone disease. Patients in the symptomatic group also underwent
more pre-operative investigations than those in the asymptomatic group.
Ros and Zambon observed that patients with a shorter duration of symptoms before
cholecystectomy achieved higher rate of symptom relief than those with longer
preoperative history . The present study did not find that symptom duration,
quality and periodicity of the pain predicted outcome. This is consistent with the
observations that the quality and periodicity of gallstone pain are variable 317"323. In
a study of patients admitted with acute upper abdominal pain, the pain characteristics
did not accurately predict gallstones j24.
In contrast with the finding by Vander Velpen et al 313, symptomatic relief from
heartburn or de novo development of this symptom after LC did not occur. It has
been shown that after cholecystectomy, the constant flow of bile into duodenum
induces duodenogastric reflux which is commoner in patients with dyspepsia than
OO/'
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asymptomatic patients . However, this finding is controversial and other
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investigators have not confirmed this observation 387. Incidence of food intolerance
fell after surgery but majority of our patients continue on low fat diet. The cure rate
for nausea, vomiting and early satiety is excellent as reported by Vander Velpen et al
293
Pre-operative abdominal bloating and constipation were significantly more common
in the symptomatic group. The combination of both symptoms is often present in
patients with irritable bowel syndrome. Most interestingly, history of psychiatric
disturbances was a significant predictor for post LC pain; and this has not been
previously reported. McMahon et al also found that patients with poor outcome had
higher anxiety and depression scores when they were assessed after surgery
Patients with post LC pain had a higher prevalence of normal or minimally inflamed
gallbladder. A tentative proposition is that the abdominal pain described by patients
in this subgroup was unrelated to gallstones disease but was due to irritable bowel
syndrome or non-ulcer dyspepsia. There may be a relationship between this often
• • • • OO TOQ
described as 'functional' disorder and major life events and depression ' .
Patients with non-ulcer dyspepsia are known to be more neurotic, more prone to
1QA "5 Q 1
anxiety and depression than controls J ' . On logistic regression analysis, only
bloating and previous or current consumption of antidepressant were significantly
associated with persistent pain. The model developed from these two variables could
predict PC pain with 65% accuracy. This model looks encouraging though clearly
needs further improvement. Future questionnaires should examine anxiety and
depression level perhaps using the Hospital Anxiety and Depression questionnaire.
Ultrasonographic findings such as number and size of stone; and thickness of
gallbladder wall might prove to be significant variables.
The cholecystectomy rate has increased since the introduction of the laparoscopic
approach 294. This is probably due to a reduced surgical threshold. This study
confirms the importance of defining symptoms which are due to gallstones rather
than other gastrointestinal conditions. Surgical outcome is likely to be poor if it is
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offered to difficult patients with dyspepsia who have undergone extensive
investigations. Their dyspepsia is usually poorly relieved despite acid suppression
therapy. Patients with dyspepsia and symptoms of irritable bowel symptoms i.e.
bloating and constipation, and use of psychotrophic drugs are unlikely to benefit
from LC.
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Table 9.1 Indications for laparoscopic cholecystectomy and duration of symptoms.




Chronic biliary pain 54 (64%) 12 (92%)*
Complicated gallstone disease 30 (36%) 1 (8%)
Acute cholecystitis 20 (24%) 1 (8%)
Cholestatic jaundice 6 (7%) 0
Pancreatitis 4 (5%) 0
Duration of symptoms
Less than 6 months 54 (64%) 10(77%)
More than 6 months 30 (36%) 3 (23%)
* p<0.05
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Table 9.2 Incidence of pain characteristics.
Pain characteristics Number of patients Frequency in p-value




Upper abdomen 77(92%) 13(100%) 93 NS
Lower abdomen 7(8%) 0(0%) 7 NS
Radiation to back 49(58%) 11(85%) 60 NS
Quality
Sharp 32(38%) 6(46%) 38 NS
Cramp 18(21%) 1(8%) 19 NS
Burning 6(7%) 2(15%) 8 NS
Crushing 4(5%) 1(8%) 5 NS
Dull 24(29%) 3(23%) 27 NS
Periodicity
Constant 56(67%) 7(54%) 65 NS
Colic 28(33%) 6(46%) 35 NS
Duration (minutes)
<30 50(59%) 9(69%) 61 NS
>30 34(41%) 4(31%) 39 NS
Frequencvfper week)
>1 attack 38(45%) 8(61%) 47 NS
<1 attack 46(55%) 5(39%) 53 NS
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Table 9.3 Incidence of dyspeptic and colonic svmptoms.
Symptoms Number of patients Frequency p-value




Nausea 50(60%) 8(62%) 60 NS
Vomiting 28(33%) 3(23%) 32 NS
Heartburn 29(35%) 4(31%) 34 NS
Early satiety 14((17%) 4(31%) 18 NS
Food intolerance 44(52%) 8(31%) 54 NS
Colonic Symptoms
Bloating 36(43%) 12(92%) 50 <0.001
Constipation 7 (8%) 10(77%) 11 <0.05
Diarrhoea 3(6%) 2(15%) 5 NS
Table 9.4 Incidence of abdominal surgery, psychiatric medications and histological
findings.





No surgery 50(60%) 7(54%) 59
Hysterectomy 8(10%) 1(8%) 9
Other surgery 26(31%) 5(38%) 32




Normal/mild 30(36%) 10(77%) 41









Table 9.5 Prevalence of preoperative and postoperative symptoms.
Symptom Number of patients Cure rate in
percentage*
Preoperative Postoperative
Nausea 50 3 94
Vomiting 28 10 65
Heartburn 29 28 3
Early satiety 14 2 85
Food intolerance 44 9 80
Bloating 36 11 69
Constipation 7 7 0
Diarrhoea 5 7 0
*Cure rate is defined as the proportion of those with a given symptom preoperatively
who had relief of symptom at six months.
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Table 9.6 Classification table for prediction of post-operative pain
Predicted Actual
Pain free PC Pain
Pain free 80 5
PC Pain 4 8
Accuracy % 95 65
CHAPTER TEN




Although cholecystectomy is generally regarded as a safe and successful treatment of
symptomatic gallstone disease, a close postoperative follow-up reveals that between
20 and 50% of patients after cholecystectomy continue to have some abdominal pain
308,314,315 Sphincter of Oddi (SO) dysfunction has been said to account for 16% of
such patients 326.
The gallbladder and SO are closely related in function. In the filling phase of the
gallbladder, the SO contracts while the gallbladder relaxes, resulting in influx of bile
into the gallbladder. In its emptying phase the SO relaxes to permit an outflow of
bile from the bile duct into the duodenum. It is possible that cholecystectomy alters
biliary physiology, giving rise to SO dysfunction in some cases. The present study
examined SO motility before and six months after laparoscopic cholecystectomy.
10.2 Patients and Methods
10.2.1 Patients selection
Seven female patients known to have symptomatic gallstone confirmed on
ultrasonography were recruited into the study. They were all awaiting LC for their
gallbladder disease. The exclusion criteria were stones in the common bile duct as
suggested by cholestatic liver function test and ultrasound scan; history of
pancreatitis; previous gastric surgery and vagotomy; medication with motility,
anticholinergic or psychotropic drugs; presence of diabetes, neuropathy and severe
cardiovascular and respiratory disease. All patients completed a symptom
questionnaire, which detailed aspects of their presenting history, other abdominal
symptoms and medication.
10.2.2 Biliary manometry
Biliary manometry was performed 2-3 weeks before and six months after
laparoscopic cholecystectomy. After overnight fast, patients were sedated with 5-10
mg of midazolam intravenously. Biliary manometry was performed by the standard
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water perfusion technique with triple-lumen polyethylene manometric catheter as
described in section 5.3.
10.2.3 Analysis of manometric recordings
Manometric tracings were coded and analysed by an experienced observer who was
blinded to the status of patients.
10.2.4 Statistical analysis
All data are reported as mean+SEM unless otherwise stated. Paired Student's tests
were used to compare for changes in motility variables before and after LC. Baseline
value was defined as the value obtained before stimulation with CCK.
The studies were approved by the Lothian Ethical Subcommittee for Medicine and
Oncology.
10.3 Results
Five patients successfully completed the study and were considered for analysis. In
one patient the bile duct could not be cannulated; one further patient declined to
return for follow-up manometry after LC. The median age for the remaining five
patient was 52 years (Range 38-61). The median duration of symptomatic gallstone
disease was 6 months (Range 2-18). None of the patients who completed the study
had features of irritable bowel syndrome as defined by the modified Rome criteria
•2Q9
. All of the patients underwent uncomplicated LC and reported excellent
symptomatic relief after surgery . One patient developed mild pancreatitis after her
repeat biliary manometry and had an uneventful recovery.
The results of the SO motility variables are shown in table 10.1. The mean common
bile duct pressure was 5.5+3.0 before LC. The value remained unchanged after
surgery. There was no significant change in the baseline motility variables after LC.
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SO manometry was possible for approximately 2 minutes after CCK injection.
Longer recordings were not possible because CCK appeared to induce retching and
intolerance.
Before LC, CCK injection consistently reduced or abolished SO phasic activity with
a small and insignificant reduction in basal pressure that remained around 24 mmHg
(see figure 10.4 for typical SO manometry tracing after intravenous injection with
CCK ). After LC, CCK failed to reduce SO phasic activity. The duration of phasic
activity was the only motility parameter which was significantly reduced by CCK
after LC from 6.1+0.2seconds to 4.4+0.6 seconds. No significant reduction was noted
in the amplitude and frequency of phasic waves.
The values for the amplitude, frequency, duration and motility index of CCK
stimulated sphincteric phasic activity after LC were significantly elevated when they
are compared with similar CCK stimulated values before surgery. The changes in
amplitude, frequency and duration of sphincteric phasic activity for individual
patients with CCK stimulation before and after surgery are shown graphically in
figure 10.1 to 10.3. Before LC the motility index decreased from ( 491+96
mmHgsec) to ( 81+35 mmHgsec ) after CCK. There was only a slight reduction in
the motility index with CCK stimulation after LC ( from 416+79 to 351+43
mmHgsec). The motility index following CCK stimulation after LC was
significantly higher than that before surgery ( p<0.01 ). A "paradoxical response" to
CCK was not observed in any patient after LC.
10.4 Discussion
Six months after LC, the SO loses its inhibitory response to CCK. This finding has
not been previously documented. Tanaka et al measured bile duct pressure before
and 3 weeks after cholecystectomy using a microtransducer method 393. They found
that after cholecystectomy, SO spasm induced by morphine injection caused
significantly higher bile duct pressure than before surgery. However, caerulein
promptly reduced the pressure by relaxing the SO. Their finding suggests that the
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gallbladder functions as a pressure reservoir during spasm of SO before
cholecystectomy.
The variables of baseline SO motor activities i.e. the recordings obtained before
CCK, are consistent with the values obtained by other workers using similar
perfusion technique 34 '350-j:,C CCK injection frequently provoked agitation and
restlessness although satisfactory recordings were obtained in all subjects for a
minimum of two minutes. The reason behind the induction of agitation is unknown
but CCK is known to provoke panic attacks in healthy volunteers I5°. Before LC,
CCK injection induced relaxation of the SO. There was reduction of the amplitude,
frequency and motility index in all the patients. In some patients, there was abolition
of all phasic activity during the recording interval.
Our findings in man are analogous to those reported by Grace and Pitt in cats j94.
These investigators showed that basal SO motility was unaffected by
cholecystectomy and that the sphincter was not relaxed by intraduodenal fat infusion
or by an injection of CCK. It is also known that injection of tetrodotoxin or
lignocaine into the cystic duct of animals prevented SO relaxation in response to
gallbladder distension 67'69-70. it is therefore likely that gallbladder and SO function
are co-ordinated by nerve fibres which pass from the gallbladder to the SO and such
fibres have been demonstrated by anatomical dissection :,0'67>68.
We speculate that in man, as in experimental animals, post-cholecystectomy SO
dysmotility in response to CCK is due to denervation which occurs as a consequence
of cystic duct amputation.
The actions of CCK on the gallbladder and SO are known to be mediated by
myogenic and neuronal receptors. In the gallbladder, CCK stimulates postganglionic
cholinergic neurones and this action is blocked by atropine n. CCK also stimulates
gallbladder smooth muscle directly, since the atropine resistant effect is unaltered by
complete denervation with tetrodotoxin. CCK inhibits the SO by stimulating
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postganglionic nonadrenergic noncholinergic inhibitory neurones, and this action is
inhibited by tetrodotoxin but not atropine. CCK also directly contracts the SO by
stimulating excitatory receptors upon the smooth muscle, and this action is not
inhibited by tetrodotoxin 1Under physiological conditions it is likely that CCK has
a neurally mediated inhibitory effect upon the SO that overrides the direct excitatory
effect of the hormone upon the SO smooth muscle. These conflicting dual effects of
CCK have been demonstrated in other experimental situations. For example, after
truncal vagotomy in prairie dogs, there is an increase in baseline resistance to flow
f\") • ...
through the SO and an increase in frequency and amplitude of phasic contractions
of the SO63.
Thus we speculate that following cholecystectomy, denervation leads to loss of the
CCK mediated neural inhibitory effect of the SO with preservation of its direct
excitatory effect.
The patients described in this study all had an excellent symptomatic response to
cholecystectomy with complete abolition of pre-operative biliary type pain. We
nevertheless speculate that our findings are relevant to the "postcholecystectomy
syndrome" of abdominal pain, disordered serum liver function tests, delayed bile
duct emptying and abnormal SO manometry 377. A range of SO motility profiles
have been reported in such patients; fixed SO tonic hypertension is probably due to
fibrosis occurring as a consequence of common bile duct surgery. A range of phasic
motor pattern disturbances including "tachyoddia" and a paradoxical response to
CCK j2/-j2S are more difficult to explain, but our findings may be relevant to such
observations.
Disordered SO motility may lead to elevation of the bile duct pressure due to loss of
the pressure reservoir effect of the gallbladder 393 and this could give rise to biliary
pain in some patients. We have shown that disordered SO motility in response to
CCK can be a consequence of cholecystectomy and it is not inconceivable that an
exaggeration of this could cause pain in susceptible individuals with irritable bowel
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syndrome thus leading to the post-cholecystectomy syndrome. These patients are
known to have reduced pain threshold to distension throughout the gut 395"397.
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Table 10.1 Sphincter ofOddi motility variables (Mean+SEM) before and after
laparoscopic cholecystectomy.
Before LC After LC
Mean CBD pressure (mmHg) 5.5+3 6.8+2.3
Baseline
SO pressure (mmHg) 24+7 27+3
SO frequency (per minute) 5.2+0.6 4.4+0.8
SO amplitude (mmHg) 94+11 101+17
Duration (second) 5.7±0.8 6.1+0.2
Motility Index (mmHgsec) 491±96 416+79
After CCK
SO pressure (mmHg) 22.6+6 26±4
SO frequency (per minute) 1.6±0.7 4±0.7*
SO amplitude (mmHg) 30.5±12.5 94+11*
Duration(second) 1.9+0.8 4.4+0.6*
Motility Index (mmHgsec) 81±35 351±43*
LC means laparoscopic cholecystectomy.
*
p value is <0.05 . This is for comparison of variables with CCK injection before
and after laparoscopic cholecystectomy.
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Figure 10.1 Frequency of phasic contractions with CCK administration before and
after laparoscopic cholecystectomy.
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Figure 10.2 Amplitude of phasic contractions with CCK administration before and
after laparoscopic cholecystectomy.
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Figure 10.4 SO manometry tracing before and after intravenous injection of CCK
showing reduction of phasic contractions (top chart at paper speed of 4 cm/min and





SUMMARY, CONCLUSIONS AND THOUGHTS FOR FUTURE
184
11.1 Introduction
My work described and discussed in this thesis examined several physiological aspects
ofbiliary motility and changes in SO motility which occur after LC.
In this chapter, I would like to summarise the findings and conclusions reached from
each project, and finally to discuss the ideas and concepts I have developed.
11.2 Early gallbladder emptying
I confirmed that gallbladder emptying preceded gastric emptying of solid food. It was
demonstrated that this early phase of gallbladder emptying was accompanied by
increased plasma CCK and gastrin concentrations. Gastrin is unlikely to be responsible
for gallbladder contraction from previous investigators' observation. Neither gaseous
gastric distension nor sham feeding consistently stimulate gallbladder emptying or
release of CCK and gastrin. In a minority of subjects, sham feeding stimulated
significant gallbladder emptying which was accompanied by increase of plasma
immunoreactive CCK concentration. CCK could therefore be responsible for the early
phase of gallbladder emptying. The mechanism underlying the early release of CCK is
unclear but it could be stimulated by vagal cholinergic mechanism during the cephalic
phase. Alternatively during the gastric phase, intragastric nutrients could stimulate the
release ofbombesin which is known to stimulate CCK release in humans.
It is also possible that the early release of CCK could be due to entry of small amounts
of swallowed food into duodenum causing CCK release before the detection of labelled
solid particles in the intestine. This issue can be resolved if the threshold for CCK
release by intraduodenal nutrient stimuli is known.
11.3 NO and gallbladder emptying
Systemic infusion of the NO donors GTN and SNP impaired post-prandial gallbladder
emptying. This inhibitory effect was not secondary to hypotension or changes in
post-prandial release of CCK. Direct inhibition by NO of gallbladder smooth muscle
contraction was confirmed in vitro using isolated bovine and human gallbladder muscle
185
strips. However, negative immunohistochemical staining for neuronal NOS in
gallbladder tissues suggested that although NO directly inhibits gallbladder smooth
muscle contraction, it is unlikely to be the neurotransmitter for NANC innervation
regulating gallbladder motility. The evidence noted in this thesis failed to demonstrate
a physiological role for NOS in gallbladder motility.
11.4 Nitric oxide and the sphincter ofOddi
Topical application of GTN inhibited SO motility and duodenal contraction. 5 mg and
10 mg were found to be equally effective.
11.5 The incidence of post-laparoscopic cholecystectomy syndrome
Symptoms were prospectively assessed using standard questionnaire before and six
months after LC. Thirteen percent of patients had continuing symptoms after LC.
Abdominal bloating and consumption of antidepressant before LC were found to be
significantly associated with post-cholecystectomy pain. With these two variables, a
classification table was produced which could predict the outcomes of pain free and
persistent pain after surgery with 95% and 65% accuracy respectively.
11.6 Effects of laparoscopic cholecystectomy upon sphincter of Oddi motility
SO dysfunction may be a consequence of cholecystectomy and could lead to biliary
symptoms following surgery. In health the gallbladder and SO function are
co-ordinated by nervous and hormonal pathways. I examined the hypothesis that
cholecystectomy interfered with normal SO function by disrupting the controlling
pathways. SO manometry was performed in five women, a few days before and six
months after LC which was undertaken for uncomplicated cholelithiasis. Before LC,
an injection of CCK largely inhibited phasic SO activity and tended to reduce tonic
pressure. Following surgery, there was a loss of the inhibitory response of the SO to
CCK. The findings may be of relevant to the range of manometric abnormalities
noted in patients with SO dysfunction.
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11.7 Thoughts for future work
(1) It is possible that the early release of CCK and gallbladder emptying so induced
was due to entry of small amounts of nutrients into duodenum stimulating CCK
release before detection of labelled solid particles in the intestine. However, it would
be difficult to design an experiment in which intragastric nutrients could be
prevented from entering duodenum in order to examine the role of cephalic or gastric
phase in isolation during early gallbladder emptying. This would involve surgical
dissection with disruption of the gastro-biliary nervous pathways in experimental
animals. Theoretically, balloons could be distended in the pylorus to prevent the flow
of nutrients into duodenum but this technique is uncomfortable and does not ensure
complete blockage of gastric fluid flowing around the balloon into duodenum. We
feel that this issue can be resolved by examining the threshold of intraduodenal
nutrients for CCK release. This can be performed by naso-duodenal intubation with
fine bore catheter. Amino acids and fatty acids of varying concentrations can then be
instilled into the upper part of small bowel with simultaneous measurement of
plasma CCK concentration. If the threshold is found to be high, then it would be
unlikely that the entry of small amount of nutrients into the duodenum is responsible
for CCK release and early gallbladder emptying.
The role of vagal cholinergic stimulation of CCK release and direct stimulation of
gallbladder smooth muscle contraction can be examined by giving a group of
volunteers cholinergic blockage with atropine. Gallbladder emptying and CCK
release can then be examined after ingestion of test meals.
(2) It is possible that impaired gallbladder motility in chronic cholecystitis is due to
excessive local production ofNO by submucosal inflammatory cells. A future study
could examine diseased gallbladder muscle strips, including assessment of NOS and
in vitro response to L-NMMA.
(3) Topical application of GTN on the ampulla could facilitate cannulation of the
ampulla at ERCP. This may facilitate extraction of small to medium size bile duct
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stones without the need for either sphincterotomy or sphincteroplasty. These
hypotheses can be tested in randomised study examining ease of ductal cannulation and
stone extraction by endoscopists of similar experience with and without GTN
application.
(4) The model developed in the thesis was predictive for persistent pain after LC with
only 65% accuracy. Its specificity and sensitivity could be improved with inclusion
other variables and the model needs to be tested prospectively. Future questionnaires
could examine anxiety and depression level using validated tool such as the Hospital
Anxiety and Depression questionnaire. Ultrasonographic findings such as number
and size of stone; and thickness of gallbladder wall might prove to be significant
variables.
(5) The clinical relevance of the loss of inhibitory response of SO to CCK following
cholecystectomy is unclear. None of our patients suffered from post-cholecystectomy
pain. It would be of interest to confirm this finding in a larger population to establish
whether there is any regaining of the inhibitory response with time after LC and
whether the response differs in asymptomatic and symptomatic individuals.
It is hoped that this work and the concepts and ideas developed will inspire and link
with other projects by future members of the research group working in this area.
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APPENDIX ONE
Publications and presentations to learned societies
Some of the work of this thesis has been presented to learned societies and published in
either abstract or hill form.
Presentations to learned societies
W Luman, GD Smith, WG Haynes, DJ Webb, KR Palmer.
Nitric oxide may influence postprandial gallbladder motility; in vivo and in vitro study.
( Presented at Caledonian Society of Gastroenterology Autumn Meeting 1995 ).
W Luman, KR Palmer.
Sphincter of Oddi and cholecystectomy.
( Presented at Edinburgh Surgical Research Meeting, Royal College of Edinburgh, Jan
1996).
W Luman. JEF Ardill, E Armstrong, GD Smith, WG Haynes, DJ Webb, KR Palmer.
Nitric oxide and abnormal gallbladder function - do gut hormones have a role ?
( Presented at the British Society ofGastroenterology Spring Meeting 1996).
W Luman, S Ghosh, GD Smith, JEF Ardill, E Armstrong, KR Palmer.
Early gallbladder emptying is mediated by cholecystokinin.
( Presented at the British Society ofGastroenterology Spring Meeting 1996 ).
W Luman, WH Adams, KR Palmer, SJ Nixon, IM Macintyre, D Hamer-Hodges, G
Wilson.
Incidence of post-cholecystectomy pain after laparoscopic cholecystectomy.
( Presented at the American Digestive Disease Week 1996).
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Early gallbladder emptying - Intestinal or central?.
( Presented at the American Digestive Disease Week 1996).
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W Luman, GD Smith, WG Haynes, DJ Webb, KR Palmer.
Nitric oxide may influence gallbladder motility.
Gut 1995; 37:Suppl 2; A51 (abstract).
W Luman, WH Adams, KR Palmer, SJ Nixon, IM Macintyre, G Wilson, D
Hamer-Hodges.
The post laparoscopic cholecystectomy syndrome - a prospective study.
(Gut 1996;39:863-866)
W Luman. AJK Williams, A Pryde, GD Smith, SJ Nixon, RC Heading, KR Palmer.
The effect of cholecystectomy upon sphincter of Oddi motility.
(Gut, in press)
W Luman. A Pryde, GD Smith, RC Heading, KR Palmer.
Effect of topical glyceryltrinitrate upon sphincter of Oddi motility.
(Gut 1997; 40:541-543.)
Manuscripts submitted
W Luman. S Ghosh, GD Smith, JEF Ardill, E Armstrong, KR Palmer.
Mechanisms of early gallbladder emptying.
(submitted to Gut)
190
W Luman, JEF Ardill, E Armstrong, GD Smith, L Brett, AM Lessells, WG Haynes, DJ
Webb, KR Palmer.













1) Less than 6 months
2) More than 6 months
Have you experienced any further pain after cholecystectomy?
1) Yes
2) No
Is the pain similar to preoperative pain?
1) Yes
2) No









2) More than 30 minutes
Frequency of pain
1) More than one attack per week
2) less than one attack per week
How would you describe the character of the pain?
1) Crampy
2) Dull
3) Sharp and stabbing
4) Crushing
5) Burning
How would you describe the nature of the pain?
1) Colicky
2) Constant
Does the pain radiate to the back?
1) Yes
2) No














Have you been on antidepressant/anxiety medication, or seen a psychiatrist before?
1) Yes
2) No
Are you taking an antidepressant?
1) Yes
2) No
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